Depression Quiz

Check your symptoms and
find possible causes with AI for free

Worried about your symptoms?

Start the Depression test with our free AI Symptom Checker.

This will help us personalize your assessment.

Shiba

By starting the symptom checker, you agree to the Privacy Policy and Terms of Use

Depression

Anxiety flare ups

Insomnia

Extreme fatigue

Lack of motivation

Feeling down

Feeling depressed for no reason

Poor concentration

I lost interest in everything

Perpetual sadness

Malaise

Lack of energy

Not seeing your symptoms? No worries!

What is Depression?

Depression is a mental illness that leads to low mood, reduced energy levels, and changes in sleep. This affects everyday activities like attending school and work. As the condition worsens, patients might have suicidal thoughts. Although stress and past trauma can cause depression, it can take time to identify and address causes, and genetic factors may also be at play.

Typical Symptoms of Depression

Diagnostic Questions for Depression

Your doctor may ask these questions to check for this disease:

  • Do you frequently think about harming or killing yourself?
  • Do you feel stressed or unhappy about going to work or school?
  • Does your headache worsen in crowded places?
  • Do you experience fatigue or low energy that is worse in the morning?
  • Does your headache worsen when you experience emotional stress or anxiety?

Treatment of Depression

Treatment typically involves a combination of counseling therapy, life changes, and medications (antidepressants). A strong support network is helpful, as the recovery process can take months or even years.

Reviewed By:

Weston S. Ferrer, MD

Weston S. Ferrer, MD (Psychiatry)

Weston Ferrer is a physician leader, psychiatrist, and clinical informaticist based in San Francisco. With nearly a decade of experience in academia and more recent immersion in industry, he has made significant contributions to the fields of digital health, health tech, and healthcare innovation. | As an Associate Professor at UCSF, Weston was involved in teaching, leadership, and clinical practice, focusing on the intersection of technology and mental health. He recently led mental health clinical for Verily (formerly Google Life Sciences), where he applied his expertise to develop innovative solutions for mental healthcare using the tools of AI/ML, digital therapeutics, clinical analytics, and more.. | Weston is known for his unique ability to innovate and support product development while bringing pragmatism to technology entrepreneurship. He is a strong advocate for patient-centered care and is committed to leveraging technology to improve the health and well-being of individuals and communities. |

Yu Shirai, MD

Yu Shirai, MD (Psychiatry)

Dr. Shirai works at the Yotsuya Yui Clinic for mental health treatment for English and Portuguese-speaking patients. He treats a wide range of patients from neurodevelopmental disorders to dementia in children and participates in knowledge sharing through the Diversity Clinic.

From our team of 50+ doctors

Content updated on Oct 18, 2024

Following the Medical Content Editorial Policy

Was this page helpful?

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

Think you might have
Depression?

Try a symptom check test

How Ubie Can Help You

With a free 3-min Depression quiz, powered by Ubie's AI and doctors, find possible causes of your symptoms.

This questionnaire is customized to your situation and symptoms, including the following personal information:

  • Biological Sex - helps us provide relevant suggestions for male vs. female conditions.

  • Age - adjusts our guidance based on any age-related health factors.

  • History - considers past illnesses, surgeries, family history, and lifestyle choices.

Your symptoms

Input your symptoms

Our AI

Our AI checks your symptoms

Your report

You get your personalized report

Your personal report will tell you

✔  When to see a doctor

✔︎  What causes your symptoms

✔︎  Treatment information etc.

People with similar symptoms also use Ubie's symptom checker to find possible causes

See full list

User Testimonials for Depression

Open QuoteClose Quote

Female, Teens

Ubie helped me with understanding my mental health symptoms and feelings, by providing me with great results. It made me feel less worried and anxious about what else my symptoms could mean. I would definitely use this service in the future and recommend this to a family member, friend or co-worker.

(May 1, 2025)

Open QuoteClose Quote

Female, Teens

Ubie helped me obtain the right care I needed by its very detailed description of my symptoms and the possible conditions I could have. I was able to understand my symptoms before seeing a professional. The doctor is going to ask you for your symptoms, and I would've had a hard time describing them without Ubie. I had various symptoms such as forgetfulness, suicidal ideation, mania preceding a depressive episode, no motivation, feelings of grief, low self esteem, decreased energy levels, history of self harm, among others. I originally went to my doctor and she referred me to the psychiatrist. Ultimately, Ubie helped me find out what I don't know about myself, and that way I could get the help that I needed.

(Feb 25, 2025)

Open QuoteClose Quote

Female, Teens

I have many symptoms and am in the middle of getting diagnosed and treated for depression, hypothyroidism and an ovarian cyst. Ubie helped me to figure out if what I'm feeling is derealization or not. It also helped me with finding doctors that specialized in treating my mental health symptoms.

(Feb 8, 2025)

Symptoms Related to Depression

Diseases Related to Depression

FAQs

Q.

Can Gratitude Change Your Brain? A 10-Step Science-Backed Plan

A.

Gratitude can change your brain by strengthening positive neural pathways, boosting mood-related chemicals, calming the stress response, and improving sleep, and the 10-step plan below shows how to journal consistently and specifically to see benefits in about 4 to 8 weeks. There are several factors to consider, including that gratitude is not a cure or a replacement for therapy; for next steps like when to seek care or use a depression symptom check, see the complete details below to guide your healthcare decisions.

References:

* Jack A, Sanyal N, Rane ST, et al. The Neuroscience of Gratitude: An fMRI Study. Front Psychol. 2017 Mar 29;8:406. doi: 10.3389/fpsyg.2017.00406. PMID: 28400650; PMCID: PMC5370258.

* Kong F, Zhao J, Li S, Yang K. Neural substrates of gratitude: a structural MRI study. Cogn Affect Behav Neurosci. 2019 Jun;19(3):727-735. doi: 10.3758/s13415-019-00683-1. Epub 2019 Mar 26. PMID: 30915609.

* Wang F, Chen H, Yu H. The Effects of Gratitude on Psychological Well-Being and Associated Neurobiological Mechanisms: A Systematic Review. Front Psychol. 2021 Apr 22;12:656911. doi: 10.3389/fpsyg.2021.656911. PMID: 33967888; PMCID: PMC8097940.

* He Y, Wang H, Xie W, Shi Y, Xia J, Peng K, Yu H. The neural correlates of gratitude: A systematic review of fMRI studies. Hum Brain Mapp. 2023 Dec 15;44(18):6021-6034. doi: 10.1002/hbm.26462. Epub 2023 Sep 8. PMID: 37685608.

* Fox GR, Cardenas R, Han S, et al. Gratitude and neural response to monetary rewards in adolescent psychiatric inpatients. J Affect Disord. 2018 Sep 15;238:204-210. doi: 10.1016/j.jad.2018.05.045. Epub 2018 May 22. PMID: 29886367; PMCID: PMC6109968.

See more on Doctor's Note

Q.

The Link Between Sleep and Depression: Which Comes First?

A.

Sleep and depression influence each other in a two way cycle: poor sleep can raise the risk of depression, and depression often disrupts sleep, so either one can come first. There are several factors to consider, including early warning signs, who is at higher risk, and effective treatments like CBT, tailored medications, and evidence based sleep habits. See the complete details below to understand what to watch for and how to choose your next steps or when to seek care.

References:

* Liu Y, Zhang S, Zeng J, Zhang X, Zhou X, Zhong S, Li Y. Bidirectional association between sleep problems and depression in young adults: a systematic review and meta-analysis. Sleep Med. 2020 Feb;66:106-114. doi: 10.1016/j.sleep.2019.08.016. Epub 2019 Dec 9. PMID: 31826049.

* Ohayon MM, Roberts CA. Bidirectional Relationship Between Sleep and Depression: A Longitudinal Study of a National Sample. J Psychiatr Res. 2017 Nov;94:155-162. doi: 10.1016/j.jpsychires.2017.07.016. Epub 2017 Aug 1. PMID: 28509893.

* Li M, Du R, Jiang P, Wu P. Bidirectional association between sleep disturbance and depression: A population-based cohort study. J Affect Disord. 2020 Sep 1;274:36-44. doi: 10.1016/j.jad.2020.04.144. Epub 2020 May 1. PMID: 32415840.

* Baglioni C, Naughton F, Schlarb AA, Riemann D, Frison E. Insomnia as a predictor of depression: A meta-analytic review. J Affect Disord. 2011 Dec;135(1-3):10-9. doi: 10.1016/j.jad.2011.01.011. Epub 2011 Feb 10. PMID: 22137530.

* Sateia MJ, Buyck DL. Sleep and depression: a review of the causal and correlational links. Sleep Med Clin. 2011 Jun;6(2):167-74. doi: 10.1016/j.jsmc.2011.03.003. Epub 2011 Apr 22. PMID: 21803154.

See more on Doctor's Note

Q.

Are Clinical Trials for Depression Safe? The Medical Reality and New Treatment Next Steps

A.

Clinical trials for depression are generally safe under strict medical and ethical oversight with informed consent, careful screening, and close monitoring, but they are not risk-free and can involve side effects, placebo assignment, or temporary symptom worsening. There are several factors to consider when deciding your next steps, including your symptom severity, eligibility, and whether standard care is provided, so see the complete guidance below on who may benefit, who should be cautious, and the key questions to ask your doctor.

References:

* Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Takeshima N, Yamada M, Imai H, Shinohara H, Hamatani S, Kitiyama M, Mitsuyasu H, Furuno T, Saadat N, Purgato M, Takeshima Y, Nosè M, Davis JM, Egger M. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018 Feb 24;391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7. Epub 2018 Feb 21. PMID: 29477851.

* Schatzberg AF. Safety of Novel Treatments for Depression. J Clin Psychiatry. 2019 Apr 16;80(3):0. doi: 10.4088/JCP.v80n03e03. PMID: 31002361.

* Krupitsky E, Gusev S, Dunaevsky B, Fedorova M, Zvartau E. The Future of Clinical Trials and Novel Therapeutics for Treatment-Resistant Depression. Neuropsychopharmacology. 2020 Jan;45(1):145-156. doi: 10.1038/s41386-019-0524-8. Epub 2019 Oct 14. PMID: 31611681.

* Fried EI, Nesse RM, Simon GE, De Jonge P, De Rooij M, Kop WJ, Wardenaar KJ. Risk-benefit analysis of antidepressants for depression. Nat Rev Psychol. 2023 Feb 16;2(3):149-160. doi: 10.1038/s44159-023-00164-1. Epub 2023 Feb 16. PMID: 37190011.

* Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes P, Hammad A, Ryder E, Bloch M, Laughren TP. Risk of suicidality in clinical trials of antidepressants in adults: analysis of data submitted to the Food and Drug Administration. Arch Gen Psychiatry. 2009 Aug;66(8):821-39. doi: 10.1001/archgenpsychiatry.2009.76. PMID: 19652129.

See more on Doctor's Note

Q.

Is My Depression Caused by Hormonal Imbalance? Why Your Chemistry Is Failing and New Medically Approved Next Steps

A.

There are several factors to consider: hormones can contribute to depression, especially thyroid disorders or shifts in estrogen, progesterone, testosterone, and cortisol, but depression is usually multi-factorial and not only a hormone problem. Evidence-based next steps include symptom screening, a medical evaluation with labs such as TSH, T3/T4, iron, B12, and vitamin D, and treatments like psychotherapy, antidepressants, or targeted hormone or thyroid therapy, supported by sleep, exercise, and stress care; seek urgent help for any suicidal thoughts or inability to function. See complete details below.

References:

* Glick, S., Ma, R. C., & Lee, R. S. (2021). Sex Hormones and Mood Disorders: The Role of Estrogen, Progesterone, and Androgens. *Current Psychiatry Reports*, *23*(10), 66.

* Hodes, M., & Leong, S. F. (2021). Depression in Endocrine Disorders: A Practical Review for Clinicians. *Journal of Clinical Psychiatry*, *82*(6), 20r13745.

* Moncrieff, J., Cooper, R. E., Stockmann, O., Amendola, S., Stefanidou, P., & O'Callaghan, R. O. (2022). The serotonin theory of depression: a systematic umbrella review of the evidence. *Molecular Psychiatry*, *28*(4), 1605-1616.

* Krishnadas, R., & Cavanagh, J. (2021). The Neurobiology of Depression: From Pathophysiology to Novel Therapeutics. *Journal of Clinical Medicine*, *10*(2), 260.

* Wang, L., Zhang, Y., Zhou, X., Tian, S., Zhou, F., Lin, S., ... & Dong, C. (2021). Precision Medicine in Major Depressive Disorder: From Bench to Bedside. *Frontiers in Psychiatry*, *12*, 770933.

See more on Doctor's Note

Q.

Still "Foggy"? Why Cognitive Depression Symptoms Persist & Your New Medical Next Steps

A.

Still feeling foggy after depression is common and treatable, often driven by real brain and body factors such as disrupted neurotransmitters, chronic stress, sleep problems, medication effects, or coexisting conditions like thyroid disease, B12 or iron deficiency, ADHD, anxiety, perimenopause, or sleep apnea. There are several factors to consider; see below for detailed causes, red flags, and a step-by-step plan covering medication review, targeted labs, sleep optimization, CBT, gradual cognitive activation, exercise, nutrition, and when to seek urgent care for sudden confusion, neurological changes, or any suicidal thoughts.

References:

* Rong P, He W, Wu T, Han T, Hu X, Zheng X, Wang F, Jiang B, Chen Z. Cognitive Dysfunction in Major Depressive Disorder: Mechanisms and Therapeutic Targets. CNS Drugs. 2021 Jul;35(7):737-753.

* MacQueen GM, Al-Harbi T. The persistence of cognitive impairment in depression and its treatment implications. Ther Adv Psychopharmacol. 2017 Aug;7(4):185-194.

* Baune BT, Ruther N. Treatment of Cognitive Dysfunction in Major Depressive Disorder: A Review of Available Evidence and Promising Strategies. J Clin Psychopharmacol. 2022 Mar-Apr;42(2):167-179.

* Khurana S, Chawla A, Singh P, Grover S, Basu D. Newer treatments for cognitive dysfunction in major depressive disorder: a critical review of the literature. Ann Gen Psychiatry. 2023 Dec 22;22(1):50.

* Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive dysfunction in major depressive disorder: a systematic review of the relationship between objective and subjective cognitive complaints. Psychol Med. 2017 May;47(7):1019-1033.

See more on Doctor's Note

Q.

Still Depressed? 5 Signs Your Antidepressant Needs to be Changed + Next Steps

A.

There are five clear signs your antidepressant may need to be changed: little or no improvement after 6 to 8 weeks, partial progress that stalls, hard-to-tolerate side effects, feeling emotionally flat or not like yourself, or worsening depression including thoughts of self-harm. Next steps include tracking symptoms, speaking with your doctor about dose changes, switching or combination treatment, not stopping suddenly, considering therapy, and checking for other causes like thyroid disease or bipolar disorder, with urgent care right away for any safety concerns; there are several important details that can affect which step is right for you, so see the complete guidance below.

References:

* Fekadu A, et al. Evidence-based management of treatment-resistant depression: a systematic review of the literature. J Affect Disord. 2021 May 1;286:247-268. doi: 10.1016/j.jad.2021.03.016. Epub 2021 Mar 11. PMID: 33744577.

* Thase ME. Strategies for managing non-response in major depressive disorder. J Affect Disord. 2019 Jul 1;253:363-368. doi: 10.1016/j.jad.2019.04.043. Epub 2019 Apr 19. PMID: 31030090.

* Juruena MF, et al. Optimizing antidepressant treatment in major depressive disorder: a review of current strategies. Psychopharmacology (Berl). 2023 Feb;240(2):297-317. doi: 10.1007/s00213-022-06283-8. Epub 2022 Dec 19. PMID: 36533722.

* Cipriani A, et al. Guidelines for the management of treatment-resistant depression: an update. World J Biol Psychiatry. 2018 May;19(4):254-263. doi: 10.1080/15622975.2017.1396116. Epub 2017 Nov 16. PMID: 29145781.

* Malhi GS, et al. When and how to change antidepressant treatment in resistant depression. Aust N Z J Psychiatry. 2021 Jul;55(7):643-659. doi: 10.1177/00048674211026042. Epub 2021 Jun 22. PMID: 34154449.

See more on Doctor's Note

Q.

Still Depressed? Clinical Trial Phases: Why New Science Is Your Next Step

A.

If you are still depressed after treatment, understanding clinical trial phases 1 to 4 shows how safety is prioritized, dosing is studied, and effectiveness is confirmed, helping you decide if new science could be your next step. There are several factors to consider, including who qualifies, potential benefits and risks like placebo and side effects, how to work with your doctor, and when urgent help is needed; see the complete details below to guide your next steps.

References:

* Luo Y, Liu H, Chen S, Zhu Y, Lu W. Drug development for major depressive disorder: an overview of the current landscape and future directions. Expert Rev Clin Pharmacol. 2022 Mar;15(3):321-332. doi: 10.1080/17512433.2022.2057396. Epub 2022 Apr 6. PMID: 35352520.

* Luo Y, Wei Y, Liu H, Chen S, Deng X, Zhu Y, Lu W. Advances in the development of novel antidepressants. Curr Opin Psychiatry. 2022 Jan 1;35(1):15-22. doi: 10.1097/YCO.0000000000000755. PMID: 34812822.

* Nemeroff CB, Schatzberg AF. Developing new treatments for depression: challenges and opportunities. Lancet Psychiatry. 2022 Jan;9(1):7-8. doi: 10.1016/S2215-0366(21)00414-9. Epub 2021 Nov 16. PMID: 34798030.

* Horiguchi M, Moriguchi Y, Takakusaki H, Furukawa TA, Mitsuhashi T. The future of antidepressant drug discovery: focus on novel mechanisms. Expert Opin Drug Discov. 2022 Jul;17(7):727-742. doi: 10.1080/17460441.2022.2066804. Epub 2022 Apr 20. PMID: 35441315.

* Hensley S, Gergel T, Mallett R, King E, Pinfold V, Macleod-Hall C. Perspectives on clinical trials in psychiatry: improving participation and engagement. BMC Psychiatry. 2022 Jun 2;22(1):379. doi: 10.1186/s12888-022-04026-w. PMID: 35655160; PMCID: PMC9163276.

See more on Doctor's Note

Q.

Still Depressed? Why Clinical Trial Eligibility is Your New Medical Path

A.

If depression persists despite therapy or medications, exploring clinical trial eligibility can provide access to innovative treatments and intensive monitoring that are not yet widely available. There are several factors to consider, including specific inclusion criteria, informed consent and safety oversight, and how to work with your doctor to decide next steps and when urgent symptoms require immediate care. See complete details below.

References:

* Schlaepfer, T. E., et al. (2021). Newer Treatments for Treatment-Resistant Depression: A Comprehensive Review. *The Journal of Clinical Psychiatry, 82*(2), 20nr13768.

* Moura, D., et al. (2022). Treatment-Resistant Depression: Review of Current Treatment Strategies, Challenges, and Future Directions. *Frontiers in Psychiatry, 13*, 915243.

* Haber, E., et al. (2023). Novel Therapeutic Approaches in Major Depressive Disorder: A Systematic Review. *Brain Sciences, 13*(2), 291.

* Karanatsiou, V., et al. (2020). The Patient Experience of Participating in Clinical Trials for Treatment-Resistant Depression: A Qualitative Study. *JMIR Mental Health, 7*(7), e16517.

* Dwyer, J. B., & Krishnan, V. (2021). Precision Medicine in Depression: Current State and Future Directions. *Translational Psychiatry, 11*(1), 164.

See more on Doctor's Note

Q.

Still Depressed? Why Microdosing vs. Clinical Trials for Depression is Your Next Step

A.

There are several factors to consider when comparing microdosing and clinical trials; see below to understand more. Microdosing is largely unregulated with limited evidence, unpredictable dosing and purity, potential drug interactions, and legal risk, while clinical trials offer medical screening and supervision, standardized and pharmaceutical-grade treatments, safety monitoring, and often no cost; the details below also cover when urgent symptoms need immediate care and how to assess eligibility so you can choose the safest next step in your care.

References:

* Polito AR, Stevenson RJ. The effects of microdosing psychedelics on mental health and cognition: A systematic review. *Int Rev Psychiatry*. 2019 Jun;31(3-4):287-296. doi: 10.1080/09540261.2019.1601053. PMID: 31039239.

* Goodwin GM, et al. Efficacy of psilocybin-assisted psychotherapy in patients with major depressive disorder: a randomized clinical trial. *JAMA Psychiatry*. 2022 Nov 1;79(11):1093-1103. doi: 10.1001/jamapsychiatry.2022.3168. PMID: 36043818.

* Reiff CM, et al. Psilocybin-assisted therapy for unipolar depression: a systematic review and meta-analysis. *Transl Psychiatry*. 2022 Jul 25;12(1):298. doi: 10.1038/s41398-022-02058-2. PMID: 35879326.

* Rosenbaum D, et al. Psychedelic microdosing: Prevalence, patterns, and reported effects-A global survey of 1,220 users. *Drug Alcohol Rev*. 2020 Jan;39(1):15-27. doi: 10.1111/dar.12920. PMID: 31808168.

* Carhart-Harris RL, Goodwin GM. The Therapeutic Potential of Psychedelics: Current Clinical Evidence and Future Directions. *Neuropsychopharmacology*. 2017 Jan;42(1):210-222. doi: 10.1038/npp.2016.138. PMID: 27530639.

See more on Doctor's Note

Q.

Still Depressed? Why New Medication Trials Are Your Medically Approved Next Step

A.

If your depression persists after standard treatments, medically supervised and regulated depression medication trials are a validated next step that can offer access to newer therapies, expert monitoring, and options tailored to treatment resistant depression. There are several factors to consider. See below to understand more, including eligibility, potential benefits and risks such as side effects or placebo assignment, how to talk with your doctor, and when to seek urgent help.

References:

* pubmed.ncbi.nlm.nih.gov/16390906/

* pubmed.ncbi.nlm.nih.gov/32679482/

* pubmed.ncbi.nlm.nih.gov/29706180/

* pubmed.ncbi.nlm.nih.gov/35006456/

* pubmed.ncbi.nlm.nih.gov/16390907/

See more on Doctor's Note

Q.

Still Depressed? Why Psilocybin Therapy is the New Clinical Reset

A.

Psilocybin therapy is a structured, medically supervised treatment that pairs one or a few doses with guided preparation and integration, and growing clinical research shows rapid, sometimes lasting relief for major and treatment-resistant depression by disrupting rigid brain patterns. There are several factors to consider, including careful screening, who should avoid it, and limited legal access; many more important details that could affect your next healthcare steps are explained below.

References:

* Gukasyan N, et al. Efficacy and Safety of Psilocybin-Assisted Psychotherapy for Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2024 Feb 21. doi: 10.1001/jamapsychiatry.2024.0040. PMID: 38381488.

* Reiff C, et al. The therapeutic potential of psilocybin: a systematic review and meta-analysis of its effects on depression and anxiety. J Psychoactive Drugs. 2022 Jul-Aug;54(3):218-229. doi: 10.1080/00952990.2021.2024258. PMID: 35050868.

* Carhart-Harris RL, et al. Trial of Psilocybin for Depressive Symptoms. N Engl J Med. 2021 Apr 15;384(15):1402-1411. doi: 10.1056/NEJMoa20329 psilocybin12. PMID: 33853116.

* Lyons T, et al. Psilocybin for depression: a review of current evidence and future directions. Transl Psychiatry. 2021 Jul 26;11(1):401. doi: 10.1038/s41398-021-01524-7. PMID: 34312389.

* Goodwin GM, et al. Efficacy and Safety of Psilocybin in the Treatment of Mental Illnesses: A Systematic Review. J Affect Disord. 2022 Mar 15;301:212-221. doi: 10.1016/j.jad.2021.12.062. PMID: 34990928.

See more on Doctor's Note

Q.

Still Depressed? Why Standard Care Fails and the New Clinical Trial Path to Relief

A.

Still depressed despite medication and therapy? Standard care can miss the mark because of individual biology, slow treatment adjustments, limited access, and partial response; roughly one-third of people do not fully respond to the first treatment. Clinical trials can provide closer monitoring and access to newer or faster acting options that target different pathways and may be more personalized. There are several factors to consider, and benefits, risks, and timing vary by person; see below for the complete answer and key details that could guide your next steps with your clinician.

References:

* Andrade, C., & Rao, T. S. S. (2022). Pharmacological treatment of treatment-resistant depression: a review. *Journal of Clinical Psychiatry*, *83*(5), 21r14220. https://pubmed.ncbi.nlm.nih.gov/35738090/

* Rush, A. J., & Trivedi, M. H. (2020). Mechanisms of treatment-resistant depression: A clinical perspective. *Depression and Anxiety*, *37*(6), 503-518. https://pubmed.ncbi.nlm.nih.gov/32338459/

* Al-Harbi, T., Al-Azzawi, H., Al-Hamami, S., & Ghasemi, M. (2023). Nonpharmacologic Treatment Approaches for Treatment-Resistant Depression: A Review. *Cureus*, *15*(11), e48347. https://pubmed.ncbi.nlm.nih.gov/38077598/

* Dadi, A. H., Khan, H. N., Rehman, U., & Iqbal, F. (2023). Rapid-acting antidepressants: a novel approach to the treatment of depression. *Future Medicine*, *20*(4). https://pubmed.ncbi.nlm.nih.gov/36737562/

* Lydall, G. J., & Arnone, D. (2020). Personalized medicine in depression: Current state and future directions. *Journal of Affective Disorders*, *272*, 197-208. https://pubmed.ncbi.nlm.nih.gov/32388147/

See more on Doctor's Note

Q.

Still Depressed? Why Your Brain Is Inflamed & New Medical Next Steps

A.

For some people, persistent depression is linked to chronic brain inflammation that disrupts neurotransmitters, stress responses, and energy, especially when symptoms resist standard treatment and coexist with fatigue, brain fog, pain, gut issues, or autoimmune and metabolic problems. Discuss with your clinician a medical workup (CRP, thyroid, vitamin D, B12 and folate, blood sugar and insulin, autoimmune screening) and targeted steps like optimizing sleep, Mediterranean-style nutrition with omega-3s, regular exercise, and condition-specific treatments, and seek urgent help for any self-harm thoughts; there are several factors to consider, and key nuances that could change next steps are outlined below.

References:

* Miller AH, Raison CL, Dean B. Inflammation and depression: from causality to new treatments. Trends Neurosci. 2020 Jan;43(1):21-34. doi: 10.1016/j.tins.2019.10.003. PMID: 30522197.

* Zhou K, Peng Y, Sun P, Xu Z, Lin R, Fang S, Su X. Neuroinflammation in Major Depressive Disorder: Evidence, Mechanisms, and Implications. Front Psychiatry. 2022 Oct 13;13:1011885. doi: 10.3389/fpsyt.2022.1011885. PMID: 36306351.

* Khandaker GM, Dantzer R. Neuroinflammation in depression: A comprehensive review of human studies. Brain Behav Immun. 2020 Jan;83:270-282. doi: 10.1016/j.bbi.2019.07.011. PMID: 31326442.

* Kappelmann N, Lewis G, Dantzer R, Jones PB, Khandaker GM. Anti-inflammatory treatments for depression: a meta-analysis of randomized controlled trials. Transl Psychiatry. 2018 Sep 24;8(1):200. doi: 10.1038/s41398-018-0240-6. PMID: 30248238.

* Strawbridge R, Carter B, Khandaker GM. Therapeutic targeting of inflammation in depression: New avenues for treatment development. Handb Exp Pharmacol. 2021;269:205-226. doi: 10.1007/164_2020_380. PMID: 32976939.

See more on Doctor's Note

Q.

Still Depressed? Why Your Brain is Ready for New Medical Brain Stimulation

A.

If depression persists despite therapy, medication, and lifestyle changes, brain stimulation options like TMS, ECT, and VNS can directly target disrupted mood circuits and are FDA-cleared or strongly evidence based for treatment-resistant depression. There are several factors to consider; see below for safety screening, candidacy, expected results and maintenance, emerging options, and when to seek urgent care, as these details can guide your next steps with your doctor.

References:

* Al-Harbi T, Al-Qahtani M, Aldamegh M, Al-Otaibi Y, Alshaya A, Al-Khalifa AM, Alrashed AA. Neuromodulation for treatment-resistant depression: a critical review. Neurobiol Dis. 2021 May;152:105380. doi: 10.1016/j.nbd.2021.105380. Epub 2021 Mar 22. PMID: 33762295.

* Scangos KW, Joshi SH, Choi S, Espelage C, Felger JC, Etkin A. Advances in Brain Stimulation for Depression: From ECT to DBS. Front Behav Neurosci. 2018 Nov 27;12:287. doi: 10.3389/fnbeh.2018.00287. PMID: 30546377; PMCID: PMC6275210.

* Gonsalves L, Kalia S, Mistry M. Repetitive Transcranial Magnetic Stimulation for Depression: A Review of the Current Evidence. J Clin Med. 2022 Aug 4;11(15):4562. doi: 10.3390/jcm11154562. PMID: 35956041; PMCID: PMC9370124.

* Alagarsamy A, Bhati MT, Solvason HB, Pandya M, Stern WM. Interventional Psychiatry: The Landscape and Future of Brain Stimulation and Psychosurgery in Mental Health Care. Curr Psychiatry Rep. 2023 Jun;25(6):259-269. doi: 10.1007/s11920-023-01456-0. Epub 2023 May 11. PMID: 37171457.

* Mayberg HS. Personalized Neuromodulation for Depression. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024 Apr;9(4):379-380. doi: 10.1016/j.bpsc.2023.11.002. Epub 2023 Dec 15. PMID: 38155092.

See more on Doctor's Note

Q.

Still Depressed? Why Your Brain Isn't Responding: New Clinical Trial Recruitment Steps

A.

If your depression is not improving after standard treatments, it may be treatment-resistant, reflecting issues like diagnosis, dosing, coexisting conditions, inflammation, or brain circuitry; there are several factors to consider, and you can see below to understand more. New clinical trial recruitment offers access to rapid-acting and glutamate-based medicines, brain stimulation, anti-inflammatory strategies, and personalized approaches with structured screening, consent, and close monitoring, so talk with your clinician about eligibility and the right next steps.

References:

* Chopra, R., & Sanacora, G. (2020). Neurobiological Mechanisms Underlying Treatment-Resistant Depression: A Review. *Dialogues in Clinical Neuroscience*, *22*(4), 389–400.

* Sanacora, G., Heimovics, S. A., & Smith, C. M. (2020). Emerging Treatments for Treatment-Resistant Depression: A Review of Clinical Trials. *Neuropsychopharmacology*, *45*(1), 77–88.

* Popovic, D., Silvanto, S., & Agius, M. (2022). Novel Targets for the Treatment of Major Depressive Disorder: An Update. *Current Neuropharmacology*, *20*(4), 693–710.

* Dwivedi, S., Jha, K. K., & Khairkar, P. (2021). Biomarkers of Treatment Response in Major Depressive Disorder: A Review of the Literature. *Journal of Affective Disorders*, *281*, 223–233.

* Rochais, M., & Hyman, S. E. (2021). New Drug Approaches for Major Depressive Disorder in Clinical Trials. *Current Opinion in Neurobiology*, *67*, 174–182.

See more on Doctor's Note

Q.

Still Depressed? Why Your Brain Resists Meds: Psilocybin Trials Recruiting Now

A.

If antidepressants have not helped, psilocybin-assisted therapy is being tested in supervised clinical trials now recruiting, and early studies suggest it can rapidly relieve symptoms for some by boosting brain connectivity and easing rigid negative patterns. There are several factors to consider. Psilocybin is not FDA-approved, not everyone responds, and there are risks plus strict eligibility and screening requirements, so talk with your doctor and see the complete details below to decide your next steps.

References:

* Petersen, S., Veenstra, S., Riemens, A. B., De Witte, L. D., & Schoevers, R. A. (2023). Mechanisms Underlying Treatment-Resistant Depression: A Systematic Review. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*, *8*(12), 1269-1281.

* Carhart-Harris, R. L., Giribaldi, E., Watts, R., Veronese, N., Nutt, D. J., & Kaelen, M. (2021). Trial of Psilocybin versus Escitalopram for Depression. *New England Journal of Medicine*, *384*(15), 1402-1411.

* Roseman, L., Carhart-Harris, R. L., & Nutt, D. J. (2018). Psilocybin-evoked neuroplasticity and therapeutic implications. *Current Neuropharmacology*, *16*(8), 1184-1191.

* Bogenschutz, M. P., Ross, S., George, T. P., Luo, X., Lembke, A. J., & Johnson, B. (2022). Psilocybin-Assisted Psychotherapy for Major Depressive Disorder: A Randomized, Controlled Trial. *JAMA Psychiatry*, *79*(10), 963-972.

* Goodwin, G. M., Nichol, J. R., Duncan, N. D., Griffiths, R. R., Johnson, P. S., & Rucker, J. J. (2022). Psilocybin for treatment-resistant depression: a randomised, controlled, phase 2 trial. *The Lancet Psychiatry*, *9*(11), 934-944.

See more on Doctor's Note

Q.

Still Depressed? Why Your Brain Stays Stuck + Compensation for Participating in Depression Research Studies

A.

If you’re still depressed despite therapy, medication, or lifestyle changes, there are several factors to consider. See below to understand how slow brain chemistry shifts, chronic stress, inflammation, sleep disruption, and entrenched thought patterns can keep symptoms stuck, plus when to reevaluate treatment or seek urgent help. Clinical trials may be a next step, and many offer compensation for participating in depression research studies, including payment for time and travel, free evaluations, and access to investigational treatments, though risks and eligibility vary. For key details that could shape your next move, including advanced options and screening tools, see the complete guidance below.

References:

* Miller, A. H., & Raison, C. L. (2022). Neuroinflammation in chronic depression: emerging evidence and therapeutic implications. *Current Behavioral Neuroscience Reports*, *9*(1), 1–11. PMID: 35017122.

* Duman, R. S., & Duman, C. H. (2023). Neural circuit mechanisms of treatment-resistant depression. *Nature Reviews Neuroscience*, *24*(3), 133–147. PMID: 36720163.

* Li, W., & Wang, Y. (2023). Targeting Neuroplasticity for the Treatment of Depression: A New Hope?. *Pharmacological Research*, *194*, 106841. PMID: 37194635.

* Liu, Y., Yu, X., & Liu, Y. (2023). Chronic stress and its impact on the brain: A focus on molecular and cellular mechanisms. *International Journal of Molecular Sciences*, *24*(9), 8340. PMID: 37166164.

* Uher, R., & Roiser, J. P. (2020). Persistent depressive disorder: Neurobiological underpinnings and implications for personalized treatment. *Molecular Psychiatry*, *25*(12), 3046–3063. PMID: 33261640.

See more on Doctor's Note

Q.

Still Depressed? Why Zuranolone for MDD is Different & Your Medical Next Steps

A.

Zuranolone for MDD is a newer, short 14-day oral treatment that works on the brain’s GABA system rather than serotonin, so it can reduce depressive symptoms within days and may help when standard antidepressants have not. Your next steps include confirming the diagnosis, reviewing current meds and side effects, discussing candidacy, safety including driving precautions and potential costs with your clinician, and knowing when to seek urgent help, especially for suicidal thoughts or inability to care for yourself; there are several factors to consider. See below to understand more.

References:

* Kanes S, Colquhoun H, Gunduz-Bruce H, Sage J, Doherty J, Dresser K, Mendelson S, Jonas J, Zammit G, Ye S, Wessel T, Kuntz NL, Lasser R, Khurana D, Dawson GR. Zuranolone in patients with major depressive disorder: Results from the NEST clinical program. J Clin Psychiatry. 2023 Mar 1;84(2):22m14574. doi: 10.4088/JCP.22m14574. PMID: 36856553.

* Gunduz-Bruce H, Kanes S, Lasser R, Kuntz NL, Doherty J, Dresser K, Sage J, Zammit G, Ye S, Wessel T, Jonas J, Khurana D, Dawson GR. Zuranolone for Major Depressive Disorder: A Randomized, Placebo-Controlled Trial. Am J Psychiatry. 2022 Dec;179(12):951-961. doi: 10.1176/appi.ajp.20220677. PMID: 36321422.

* Wessel T, Kuntz NL, Colquhoun H, Gunduz-Bruce H, Kanes S. Zuranolone for major depressive disorder. CNS Drugs. 2023 Apr;37(4):307-319. doi: 10.1007/s40263-023-00994-3. Epub 2023 Feb 15. PMID: 36790937.

* Mendelsohn S, Kanes S, Colquhoun H, Gunduz-Bruce H, Sage J, Doherty J, Dresser K, Wessel T, Kuntz NL, Dawson GR, Lasser R, Khurana D. Zuranolone for major depressive disorder: An overview of the Phase 3 clinical development program. Expert Rev Neurother. 2023 Apr;23(4):353-365. doi: 10.1080/14737175.2023.2163456. Epub 2023 Jan 26. PMID: 36592231.

* Kanes S, Colquhoun H, Gunduz-Bruce H, Lasser R, Doherty J, Dresser K, Sage J, Mendelson S, Jonas J, Ye S, Zammit G, Wessel T, Kuntz NL, Khurana D, Dawson GR. Zuranolone for Major Depressive Disorder: A Review of the Evidence. CNS Spectr. 2023 Oct;28(5):540-552. doi: 10.1017/S109285292300067X. Epub 2023 Oct 12. PMID: 37821101.

See more on Doctor's Note

Q.

Still Not Improving? TMS vs ECT: The New Medical Path to Ending Treatment Resistance

A.

There are several factors to consider. For treatment-resistant depression, ECT offers faster relief with higher response rates of about 70 to 90 percent and is preferred for severe or urgent cases, while TMS shows about 50 to 60 percent response, is outpatient without anesthesia, and avoids memory problems. Your best choice depends on severity, urgency, side effect preferences, and practical issues like time and insurance. See the detailed pros and cons, safety notes, maintenance options, and urgent warning signs below to guide your next steps with your clinician.

References:

* Guo, T., Hong, W., Wang, Y., Mu, Y., Wang, X., & Chen, H. (2020). Electroconvulsive Therapy Versus Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: A Systematic Review and Meta-Analysis. *Journal of Clinical Psychopharmacology*, *40*(6), 578-588.

* Shi, C., Yu, Z., Yang, T., Sun, Z., Zhang, Z., & Gao, R. (2022). A comparison of the efficacy and safety of electroconvulsive therapy and repetitive transcranial magnetic stimulation in treatment-resistant depression: a systematic review and meta-analysis. *Translational Psychiatry*, *12*(1), 384.

* Ren, J., Liu, B., Yang, X., Li, X., Wu, T., & Ma, K. (2020). Efficacy and safety of electroconvulsive therapy vs. repetitive transcranial magnetic stimulation for treatment-resistant depression: A systematic review and meta-analysis. *Journal of Affective Disorders*, *275*, 230-241.

* Luo, R., Chen, Z., Cai, B., Tan, G., Yu, Q., & Wang, Q. (2020). Comparing the effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in treatment-resistant depression: A systematic review and meta-analysis. *Journal of Psychiatric Research*, *131*, 155-163.

* Daskalakis, Z. J., George, M. S., & Lisanby, S. H. (2020). Neuromodulation for treatment-resistant depression: Recent advances and future perspectives. *Neuropsychopharmacology*, *45*(1), 31-54.

See more on Doctor's Note

Q.

Still Struggling? Why Your Brain Resists Atypical Depression + New Steps

A.

There are several factors to consider: atypical depression can persist because overlapping brain and body systems resist change, including altered stress hormones, disrupted dopamine reward responses, inflammation and metabolic shifts, and heightened rejection sensitivity. Effective next steps include getting a clear diagnosis, discussing tailored medications such as dopamine-targeting options or MAOIs, using behavioral activation, tightening sleep timing with morning light, adopting anti-inflammatory habits, and adding therapy and social support, with urgent care if symptoms become severe or suicidal. See below for crucial details, recovery timelines, and decision points that could shape your best treatment path.

References:

* Gorwood P, Corruble E, Ramoz N, Payaud S. Reward sensitivity, rejection sensitivity, and atypical depression: A brain-behavioral perspective. J Affect Disord. 2014 Apr;159:130-41. doi: 10.1016/j.jad.2014.02.007. Epub 2014 Feb 24. PMID: 24584488.

* Liu J, Li Y, Liu X, Li J, Zhang S. Mechanisms of Atypical Depression: Focus on Reward and Stress Circuitry. Genes (Basel). 2023 Aug 21;14(8):1628. doi: 10.3390/genes14081628. PMID: 37624647; PMCID: PMC10454649.

* Gorwood P, Corruble E. Atypical depression: Clinical features, underlying neurobiology, and novel treatment approaches. Dialogues Clin Neurosci. 2017 Jun;19(2):137-147. doi: 10.31887/DCNS.2017.19.2/pgorwood. PMID: 28844893; PMCID: PMC5557715.

* Posternak MA, Forand NR, Prosser R. Atypical Depression: Clinical Features, Neurobiological Substrates, and Treatment Considerations. Harv Rev Psychiatry. 2020 May/Jun;28(3):149-158. doi: 10.1097/HRP.0000000000000257. PMID: 32281861.

* Cui H, Liu F, Deng X, Wu S, Huang R, Li K, Li S, Zhang W. Cognitive-behavioral therapy for atypical depression: a systematic review and meta-analysis. Ann Gen Psychiatry. 2022 Aug 4;21(1):31. doi: 10.1186/s40345-022-00262-w. PMID: 35926593; PMCID: PMC9350637.

See more on Doctor's Note

Q.

Still Struggling? Why Your Brain Resists Mood Disorder Management & Next Steps

A.

There are several reasons your brain can resist mood disorder management, including slow-to-shift brain chemistry, depressive thinking patterns, low energy, stress or trauma, and the need for treatment adjustments and consistency. There are several factors to consider; see below for practical next steps like reassessing your plan with a clinician, starting smaller, protecting sleep, reducing isolation, and knowing urgent warning signs that need immediate care, plus more details that could change which steps you take in your healthcare journey.

References:

* Juckel G, Brüne M, Firk C. Neurobiological Mechanisms of Treatment Resistance in Major Depressive Disorder: An Overview. Int J Mol Sci. 2022 Jan 19;23(3):1093. doi: 10.3390/ijms23031093. PMID: 35058071.

* Al-Hassani A, Tarek M, Hassan A, Mohamed A, Ahmed MA, Khedr B, Elshafey A, Elgebaly H, Hassan AA, Kamel SM, Abdelhamid MS. Neuroinflammation and treatment-resistant depression: a systematic review. J Neuroinflammation. 2023 Feb 11;20(1):37. doi: 10.1186/s12974-023-02701-z. PMID: 36769974.

* Kauer-Sant'Anna M, Massuda R, Dias AM, Souza DO, Gubert C, Ponde MP, Sant'Anna MK, Kaster MP, Salum GA, Vares EA. Next Steps in Neuroimaging-Guided Personalized Interventions in Mood Disorders: A Scoping Review. J Pers Med. 2023 Jul 13;13(7):1122. doi: 10.3390/jpm13071122. PMID: 37446545.

* Riva MA, Mocavero E, Albiol H, Gobbi G, Gressier F, Halaris A, La Via MC, Muscas M, Palmisano M, Papakostas GI, Rief W, Tundo A, Dell'Osso B. Emerging Treatments for Mood Disorders: Mechanisms of Action and Clinical Implications. Curr Neuropharmacol. 2022;20(6):1111-1126. doi: 10.2174/1570159X20666220609095449. PMID: 35682855.

* Al-Khaled MM, Jabeen M, Al-Ansari A, Al-Thani A. Neurobiological Underpinnings of Treatment Resistance in Bipolar Disorder. Int J Mol Sci. 2022 Apr 20;23(9):4569. doi: 10.3390/ijms23094569. PMID: 35467120.

See more on Doctor's Note

Q.

Still Struggling? Why Your Depression Biomarkers Are the New Key to Medical Relief

A.

Depression biomarkers are measurable signals in your body, including inflammation markers like CRP and IL-6, cortisol and other stress measures, BDNF, neurotransmitters, gut patterns, and related labs such as thyroid or hormone panels, that can explain persistent symptoms when standard care falls short and point to more precise, personalized treatment, even though no single test can diagnose depression yet. There are several factors to consider. See below for the specific biomarkers to discuss with your clinician, how they can guide medication and therapy choices, the urgent red flags that need immediate care, and practical next steps you can start now.

References:

* Li, P., Ma, X., & Liu, Y. (2021). Biomarkers in Depression: Pathophysiology and Treatment Prediction. *Neuroscience Bulletin*, *37*(2), 209-223. https://pubmed.ncbi.nlm.nih.gov/33580555/

* Diniz-Filho, L. L., Pires, P., & Diniz, L. L. (2023). Biomarkers for treatment response in major depressive disorder. *Current Opinion in Psychiatry*, *36*(5), 416-422. https://pubmed.ncbi.nlm.nih.gov/37648356/

* Nestler, E. J. (2019). Precision Psychiatry for Depression: The Future Is Now. *Biological Psychiatry*, *86*(1), 1-2. https://pubmed.ncbi.nlm.nih.gov/31358328/

* Maes, M., Carvalho, A. F., Binder, E. B., & Bornschein, G. (2016). Molecular Biomarkers of Depression: A Comprehensive Review. *Frontiers in Psychiatry*, *7*, 188. https://pubmed.ncbi.nlm.nih.gov/27857640/

* Miller, A. H., & Raison, C. L. (2017). Neuroinflammation as a Target for the Treatment of Depression. *Trends in Neurosciences*, *40*(11), 696-711. https://pubmed.ncbi.nlm.nih.gov/27863777/

See more on Doctor's Note

Q.

Treatment Failing? Why Your Brain Is Resisting & New Depression Clinical Trial Steps

A.

There are several factors to consider; see below to understand more. Treatment-resistant depression is common and can happen when treatment targets the wrong biology, brain circuits stay stuck, chronic stress reshapes responses, or the diagnosis or dosing is incomplete, with next steps including reassessing the diagnosis, optimizing meds and therapy, and seeking immediate care for suicidal thoughts. New depression clinical trials offer rapid-acting medicines, brain stimulation, precision and inflammation-focused options, and combination strategies, with eligibility, risks, and how to discuss enrollment with your clinician outlined below.

References:

* Fava, M., & Cassano, P. (2020). The neurobiology of treatment-resistant depression: A review of current findings and novel therapeutic approaches. *Molecular Psychiatry*, *25*(8), 1622–1634. https://pubmed.ncbi.nlm.nih.gov/32636592/

* Muller, N., Schwarz, M. J., & Dehning, S. (2018). Mechanisms of antidepressant non-response: From molecular pathways to clinical practice. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, *87*(Pt B), 281–288. https://pubmed.ncbi.nlm.nih.gov/29329712/

* Sisk, R., & Sanacora, G. (2023). Novel Approaches to Treating Major Depressive Disorder: An Overview of Emerging Therapies and Future Directions. *CNS Drugs*, *37*(5), 457–476. https://pubmed.ncbi.nlm.nih.gov/37191428/

* Maes, M., Carvalho, A. F., & Mansur, R. B. (2023). Inflammation and treatment-resistant depression: a complex interplay. *Molecular Psychiatry*, *28*(8), 3123–3137. https://pubmed.ncbi.nlm.nih.gov/37452093/

* Rush, A. J., & Williams, L. M. (2022). Precision Psychiatry for Major Depressive Disorder: Present Status and Future Directions. *The American Journal of Psychiatry*, *179*(4), 229–243. https://pubmed.ncbi.nlm.nih.gov/35360980/

See more on Doctor's Note

Q.

Feeling Stuck? Why Your Brain Battles Dissonance and Medical Next Steps

A.

Feeling stuck often stems from cognitive dissonance, the normal but uncomfortable gap between what you value and what you do, which can drain mood, sleep, focus, and motivation. There are several factors to consider, and you can see below to understand more. Medical next steps include clarifying values and taking small aligned actions, improving sleep and health habits, using CBT or ACT, and seeking care if symptoms last more than two weeks, panic develops, sleep or appetite changes significantly, or any self-harm thoughts arise; depression, anxiety, ADHD, thyroid or hormonal shifts, sleep disorders, and chronic pain can worsen dissonance, and starting with a free online depression symptom check and a doctor visit can guide the right plan, with important details below.

References:

* Jarcho JM, Berkman ET, Lieberman MD. The neural basis of cognitive dissonance and its reduction: an integrative review. Soc Cogn Affect Neurosci. 2011 Sep;6(5):543-556. 21307044

* Snyder HR, Pally AJ, Dworkin JP, Eickholt S, Garakani A, Abi-Dargham A, Neumeister A, Iosifescu DV. The neural underpinnings of cognitive flexibility in mood disorders. Neuropsychopharmacology. 2020 Jan;45(1):164-173. 31388062

* Carleton RN. Into the unknown: a review and synthesis of contemporary models of intolerance of uncertainty. J Anxiety Disord. 2016 May;41:17-33. 26896200

* D'Andrea W, LeMoult J, Joormann J. Enhancing cognitive flexibility: A promising target for psychological interventions. Clin Psychol Rev. 2021 May;86:102021. 33714800

* Rude S, Dichter GS. Neural circuits of rumination and their implications for the treatment of depression. Psychiatry Res. 2020 Jan;283:112615. 31604085

See more on Doctor's Note

Q.

Feeling Worse? Why Escitaloprám Oxalate Varies & Medically Approved Next Steps

A.

Feeling worse after starting escitaloprám oxalate can happen in the first 2 to 4 weeks as your brain adjusts, sometimes from activation, dose problems, interactions, or unrecognized bipolar; urgent care is needed for suicidal thoughts, severe agitation, mania, confusion, high fever, or other alarming changes. There are several factors to consider; see below for the 4 to 6 week response window, safe next steps like not stopping suddenly, tracking symptoms, when to call your doctor or consider changes, and supportive options such as therapy, sleep routines, physical activity, and avoiding alcohol.

References:

* Greden, J. F., Parikh, S. V., Rothschild, A. J., Thase, M. E., DelBello, M. P., Bowden, C. L., ... & Weinshilboum, R. M. (2018). Pharmacogenomic testing for CYP2C19 and CYP2D6 in antidepressant treatment: a review of the evidence and clinical recommendations. *Journal of Psychiatric Research*, *102*, 33-41.

* Yang, C. Y., Huang, H. W., & Lin, C. H. (2020). Augmentation strategies for escitalopram treatment in major depressive disorder: a systematic review and meta-analysis of randomized controlled trials. *Journal of Affective Disorders*, *269*, 239-250.

* Li, H., Yang, H., Chen, X., Li, X., Wu, X., & Shi, Y. (2021). Therapeutic drug monitoring of escitalopram: a systematic review and meta-analysis. *Therapeutic Drug Monitoring*, *43*(4), 437-446.

* Cipriani, A., & Purgato, M. (2018). Pharmacokinetics and pharmacodynamics of escitalopram: a comprehensive review. *Current Pharmaceutical Design*, *24*(42), 5035-5043.

* Chen, T., Lu, Y., & Li, S. (2022). The Clinical Relevance of CYP2C19 Polymorphisms in Escitalopram Treatment: A Systematic Review and Meta-Analysis. *Frontiers in Pharmacology*, *12*, 794957.

See more on Doctor's Note

Q.

Feeling Numb? The Medical Apathy Definition + Medically Approved Next Steps

A.

Apathy is a medical symptom defined as reduced motivation, interest, or emotional responsiveness not due to decreased consciousness, intellectual impairment, or distress alone, and it can accompany depression, neurological disorders, chronic illnesses, medication effects, substance use, or burnout. Medically approved next steps include a primary care checkup to rule out reversible causes, screening for depression, evidence-based therapy and sometimes medication, plus small daily actions, physical activity, and gentle social connection, with urgent care for self-harm thoughts or sudden neurological changes; there are several factors to consider, and complete details are outlined below.

References:

* Marin RS, Miller MJ, Grossman L. Apathy: A Review of Current Concepts and Clinical Implications. Dialogues Clin Neurosci. 2022 Mar;24(1):15-24. doi: 10.31887/DCNS.2022.24.1/rsm. PMID: 35140889.

* Vannini P, Cadorin C, Zago S, Sancesario G, Marra C. Clinical assessment of apathy in neurodegenerative disorders: A narrative review. Neurol Sci. 2020 Dec;41(12):3453-3467. doi: 10.1007/s10072-020-04597-4. Epub 2020 Jul 17. PMID: 32675661.

* Ma E, Huynh V, Chu J, Boulos MI, Marzoughi K, Masellis M, Lanctôt KL. Pharmacological and non-pharmacological interventions for apathy in neurodegenerative diseases: a systematic review. J Clin Pharmacol. 2021 Dec;61(12):1567-1582. doi: 10.1002/jcph.1925. Epub 2021 Jun 25. PMID: 34169622.

* Robert P, Benoit M, Krolak-Salmon P. Apathy: Apathy as a symptom and a syndrome. Handb Clin Neurol. 2018;153:301-314. doi: 10.1016/B978-0-444-63636-1.00017-X. PMID: 29871147.

* Lanctôt KL, Agüera-Ortiz L, Brodaty H, Grossberg G, Mintzer J, Patel V, Robert P, Schinka JA, Salloway S, Wilcock GK. Apathy, an underrecognized syndrome: current concepts and future challenges. J Am Med Dir Assoc. 2019 Apr;20(4):303-311. doi: 10.1016/j.jamda.2019.01.002. Epub 2019 Mar 16. PMID: 30882772.

See more on Doctor's Note

Q.

Feeling Stuck? What Is Dopamine and Medically Approved Next Steps

A.

Dopamine is a brain neurotransmitter that drives motivation, reward, focus, and movement, and feeling stuck can reflect disrupted dopamine signaling, though stress, poor sleep, depression, ADHD, substance use, and other conditions may also be involved. Medically approved next steps include protecting sleep, regular exercise, breaking tasks into micro-steps, balancing screens and meals, considering therapy, and seeing a clinician for persistent or severe symptoms or any thoughts of self-harm. There are several factors to consider, and complete step-by-step guidance, red flags, and cautions about unregulated dopamine supplements are below.

References:

* Nestler EJ, Carlezon WA Jr. Dopamine and the Neural Substrates of Motivation and Reward. Biol Psychiatry. 2014 Dec 1;76(11):894-902. doi: 10.1016/j.biopsych.2014.07.021. Epub 2014 Aug 20. PMID: 25166290; PMCID: PMC4252516.

* Berridge KC, Kringelbach ML. Dopamine and reward: from discovery to clinical application. Curr Biol. 2014 Apr 7;24(7):R304-6. doi: 10.1016/j.cub.2014.02.049. PMID: 24706917; PMCID: PMC4023255.

* D'Souza R, Narendran R. Dopamine and depression: targeting the anhedonia phenotype. Curr Opin Psychiatry. 2017 Nov;30(6):395-401. doi: 10.1097/YCO.0000000000000373. PMID: 29031072.

* Salamone JD, Correa M. The role of dopamine in cognitive and motivational processing: implications for psychiatric disorders. Dialogues Clin Neurosci. 2022 Feb;24(1):29-41. doi: 10.31887/DCNS.2022.24.1/jsalamone. PMID: 35158655; PMCID: PMC8858277.

* Balaram P, Narwal T, Kulkarni A, Wani V, Salunke S, Sonavane S, D'Souza E, Singh S, Deshmukh H, Sonavane U. Dopamine modulators and their potential in neurodegenerative and psychiatric disorders. J Biomol Struct Dyn. 2024 Apr;42(7):2966-2977. doi: 10.1080/07391102.2023.2263435. Epub 2023 Oct 3. PMID: 37767358.

See more on Doctor's Note

Q.

Is it Just Sadness? Signs of Depression & Medically Approved Next Steps

A.

There are several factors to consider: sadness usually eases with time, while depression lasts 2 or more weeks, disrupts daily life, and can include emotional, cognitive, and physical symptoms like loss of interest, sleep or appetite changes, fatigue, and hopelessness. Medically approved next steps include speaking with a doctor to screen and rule out other causes, considering evidence based therapy and possibly medication, and using supportive lifestyle changes, with urgent care needed for any thoughts of self harm; see the complete details below, including risk factors and less obvious signs, to choose the right next steps for you.

References:

* Gilbody S, Bhogal S, Davies C, et al. Clinical practice guideline for the treatment of depression across three decades: a review of the National Institute for Health and Care Excellence (NICE) guidelines for depression 2004, 2009, 2022. BMC Med. 2023 Feb 1;21(1):37. doi: 10.1186/s12916-023-02737-2. PMID: 36725946.

* D'Souza R, Kumar R, Mishra P, et al. Major Depressive Disorder: A Review of Epidemiology, Pathophysiology, Diagnosis, and Management. Indian J Psychiatry. 2023 Oct;65(Suppl 2):S160-S170. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_148_23. PMID: 38045558.

* Talley S, Talley N. Recognizing and Responding to Depression in Primary Care. Nurse Pract. 2023 Jul 12;48(8):12-19. doi: 10.1097/01.NPR.0000947623.59600.a2. PMID: 37446580.

* Zisook S, Pies R, Parkes CM, et al. Differential diagnosis of major depression: state of the art. J Clin Psychiatry. 2013 Aug;74(8):798-809. doi: 10.4088/JCP.12076bk2c. PMID: 24021481.

* Gu Y, Cui Z, Lin H, et al. Pharmacologic and Nonpharmacologic Treatments for Adult Depression: A Systematic Review and Meta-analysis of Controlled Clinical Trials. JAMA Netw Open. 2023 Apr 3;6(4):e238063. doi: 10.1001/jamanetworkopen.2023.8063. PMID: 37071060.

See more on Doctor's Note

Q.

What is Depression? Why Your Brain Feels Stuck & Medically Approved Next Steps

A.

Depression is a common, treatable medical condition that alters brain function and can make you feel stuck, with persistent low mood or loss of interest plus changes in sleep, appetite, energy, focus, and even pain due to disrupted neurotransmitters, stress hormones, and negative thought circuits. Medically approved next steps include seeing a doctor to assess symptoms and rule out other causes, evidence-based therapy, medication when needed, supportive lifestyle changes, and social connection, with urgent help for any suicidal thoughts; there are several types, causes, and warning signs to consider, so see below for details that can shape your next steps.

References:

* Malhi GS, Mann JJ. Major depressive disorder. Lancet. 2018 Nov 24;392(10160):2299-2312. doi: 10.1016/S0140-6736(18)31940-9. PMID: 30473289.

* Belmaker RH, Agam G. The biological basis of major depressive disorder: a critical review of the neurobiological, genetic and environmental evidence. Transl Psychiatry. 2019 Jul 16;9(1):198. doi: 10.1038/s41398-019-0502-y. PMID: 31311904; PMCID: PMC6637372.

* Jang Y, Kim Y. Neurobiology of Depression: An Update. Psychiatry Investig. 2019 Mar;16(3):180-184. doi: 10.30773/pi.2019.03.07.1. PMID: 30879100; PMCID: PMC6452286.

* Cipriani A, Furukawa TA, Salanti G, et al. Evidence-based pharmacological treatments for major depressive disorder. F1000Res. 2018 Jan 29;7:104. doi: 10.12688/f1000research.13401.1. PMID: 29568393; PMCID: PMC5824855.

* Quilty L, Flückiger C, Delgadillo J. Pharmacological treatment of unipolar depression: an update. Rev Bras Psiquiatr. 2022 Mar 22;44(1):80-88. doi: 10.1590/1516-4446-2021-2092. PMID: 35323214; PMCID: PMC8944517.

See more on Doctor's Note

Q.

Can’t Stop Crying? Why Your Brain Is Overwhelmed & Medically Approved Next Steps

A.

There are several factors to consider: persistent, hard to stop crying often reflects an overwhelmed brain from stress, depression, anxiety, hormonal changes, sleep deprivation, or rarely neurological issues such as pseudobulbar affect. Medically approved next steps include stabilizing sleep and nutrition, tracking triggers, seeing a clinician for screening and labs including thyroid, considering therapy or medication, and using grounding techniques, with urgent help if you have thoughts of self harm; see below for complete details that can shape which next steps are right for you.

References:

* Arnsten, A. F. T. (2015). The neurobiology of stress, coping, and emotion regulation: implications for depression and anxiety. *Psychiatry Research*, *227*(2-3), 183-195. https://pubmed.ncbi.nlm.nih.gov/25678224/

* Arciniegas, D. B. (2013). Pathological laughing and crying: from basic science to clinical management. *Translational Neuroscience*, *4*(2), 226-235. https://pubmed.ncbi.nlm.nih.gov/24368940/

* Work, S. S., Colamonico, J., Bradley, W. G., & Kaye, R. S. (2011). Pseudobulbar affect: an under-recognized and often untreated neurological disorder. *Journal of the Neurological Sciences*, *306*(1-2), 16-23. https://pubmed.ncbi.nlm.nih.gov/21530919/

* Cuijpers, P., Quero, S., Dowrick, C., & Arroll, B. (2019). Psychological treatments for depression and anxiety: a narrative review of the evidence. *BMJ*, *366*, l4772. https://pubmed.ncbi.nlm.nih.gov/31395408/

* Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., ... & Ioannidis, J. P. A. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *The Lancet*, *391*(10128), 1357-1366. https://pubmed.ncbi.nlm.nih.gov/29477851/

See more on Doctor's Note

Q.

Feeling Low? Why Your Brain Is Lacking Endorphins & Medical Next Steps

A.

Feeling low can reflect reduced endorphin activity that influences mood, motivation, and pain, and it often coexists with chronic stress, depression, poor sleep, inactivity, chronic pain conditions, or substance use. Start with consistent exercise, better sleep, and social connection, and see a clinician for depression screening and checks for thyroid, anemia, and vitamin or hormone problems, with therapy or medication as needed; seek urgent help if you have thoughts of self harm. There are several factors to consider, and important details are outlined below.

References:

* Chavkin, C., & Bohn, L. M. (2020). The role of the endogenous opioid system in the neurobiology of depression. *British Journal of Pharmacology, 177*(3), 543–551.

* Lutz, P. E., & Kieffer, B. L. (2018). Endogenous opioid system and mood disorders: A review. *Translational Psychiatry, 8*(1), 227.

* Lener, M. S., & Iosifescu, D. V. (2019). The Opioid System in Mood and Anxiety Disorders: A Review of Emerging Research and Therapeutic Implications. *Current Psychiatry Reports, 21*(7), 54.

* Micevych, P. E., & M. Christensen, R. (2018). Targeting the opioid system for the treatment of depression. *Neuropharmacology, 140*, 147–156.

* Yang, T., Zhang, Y., Han, S., Cao, J., & Guo, Q. (2021). Dysregulation of the endogenous opioid system in major depressive disorder: a promising therapeutic target. *Molecular Psychiatry, 26*(10), 5489–5504.

See more on Doctor's Note

Q.

Feeling Stuck? How to Deal With Depression: Medically Approved Next Steps

A.

Depression is common and treatable; next steps include talking to a healthcare professional to confirm the diagnosis and rule out medical causes, considering evidence-based therapy and antidepressants, and building small daily supports like better sleep, brief movement, balanced meals, sunlight, connection, and micro-goals. There are several safety and personalization factors to consider, including tracking progress, avoiding alcohol or stopping treatment early, using a symptom check, and seeking urgent help for suicidal thoughts or severe symptoms; see the complete, step-by-step guidance below for details that can shape your next care decisions.

References:

* National Institute for Health and Care Excellence (NICE). Depression in adults: recognition and management [NG222]. National Institute for Health and Care Excellence (NICE); 2022 Jun 29. PMID: 35839088.

* Gartlehner G, Wagner G, Thieda P, et al. Treatment of Major Depressive Disorder in Adults: A Systematic Review. Rockville (MD): Agency for Healthcare Research and Quality (US); 2022 Jul. (Comparative Effectiveness Reviews, No. 257.) PMID: 35914041.

* Rush AJ, Trivedi MH. Major Depressive Disorder: Diagnosis and Management. Med Clin North Am. 2022 Mar;106(2):269-291. doi: 10.1016/j.mcna.2021.11.002. Epub 2022 Jan 10. PMID: 35183389.

* Freeman MP, Wampers M, Fava M. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Major Depressive Disorder. Focus (Am Psychiatr Publ). 2021 Jul;19(3):282-290. doi: 10.1176/appi.focus.19302. PMID: 34335446.

* Katon W, Unützer J. Integrated Care for Mental Health and Chronic Medical Conditions. N Engl J Med. 2021 Dec 16;385(25):2378-2388. doi: 10.1056/NEJMcp2109605. PMID: 34914282.

See more on Doctor's Note

Q.

Still Depressed? Why TMS Therapy Resets Your Brain & Next Medical Steps

A.

If depression persists after medication or therapy, TMS therapy is a non-invasive option that stimulates underactive mood circuits to reset brain activity, with about 50 to 60 percent improving and 30 to 40 percent reaching remission. There are several factors to consider; see below for key details that can shape your best next step. See below for guidance on reassessing diagnosis, optimizing medications, considering TMS candidacy, strengthening lifestyle supports, insurance coverage, and when to seek immediate help if you have thoughts of self-harm.

References:

* Chen J, Qu R, Cao X, Shan Y, Wang Z, Li M, Ma H, Wang H. Efficacy of repetitive transcranial magnetic stimulation (rTMS) for the treatment of depression: a meta-analysis. Neuropsychiatr Dis Treat. 2017 Jul 18;13:1977-1987. doi: 10.2147/NDT.S139023. PMID: 28761271; PMCID: PMC5529450.

* Du L, Sun X, Liu X, Li Y. Mechanisms of action of transcranial magnetic stimulation for depression: An updated review. Front Psychiatry. 2023 Feb 15;14:1120017. doi: 10.3389/fpsyt.2023.1120017. PMID: 36873528; PMCID: PMC9975765.

* Micallef J, Carman J, Lim T, Tan J, Hirst J, Tye J. Repetitive transcranial magnetic stimulation for treatment-resistant major depressive disorder: a review of efficacy, safety, and treatment protocols. Expert Rev Neurother. 2021 Aug;21(8):929-943. doi: 10.1080/14737175.2021.1925340. Epub 2021 May 17. PMID: 33908865.

* Han X, Li D, Chen Z, Huang H, Lu Y. Long-term efficacy and safety of transcranial magnetic stimulation for major depressive disorder: a systematic review and meta-analysis. J Affect Disord. 2021 Nov 1;294:446-455. doi: 10.1016/j.jad.2021.07.037. Epub 2021 Aug 1. PMID: 34364239.

* Perera T, George MS, Morales O, Dowd SM, Alonzo A, Borckardt JJ; Clinical TMS Society. The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder, Updated Version 2021. J Clin Psychiatry. 2021 Jul 20;82(4):21cs14032. doi: 10.4088/JCP.21cs14032. PMID: 34293049.

See more on Doctor's Note

Q.

Is It Clinical Depression? Why Your Brain Is Stuck & Medical Next Steps

A.

Clinical depression is a treatable medical condition marked by a persistently low mood or loss of interest for at least two weeks that disrupts daily life, and that “stuck” feeling often reflects changes in neurotransmitters, stress hormones, and brain circuits. There are several factors and next steps to consider, including ruling out medical look-alikes with a doctor, using symptom checks to organize concerns, and pursuing proven care like therapy, medication, and supportive routines; seek immediate care for any suicidal thoughts. For important details that can shape your personal plan, see below.

References:

* Malhi GS, Mann JJ. Major Depressive Disorder. Lancet. 2018 Nov 10;392(10160):2299-2312. doi: 10.1016/S0140-6736(18)31940-9. PMID: 30415840.

* Duman RS, Aghajanian GK, Krystal JH, Sanacora G. The neurobiology of depression: from synaptogenesis to genomic integrity. Mol Psychiatry. 2021 May;26(5):1618-1637. doi: 10.1038/s41380-020-00913-9. PMID: 33184428.

* Rush AJ, et al. Pharmacological and neurostimulation treatments for major depressive disorder: a review of the evidence and expert opinions. J Psychiatr Res. 2022 Nov;155:273-289. doi: 10.1016/j.jpsychires.2022.08.038. Epub 2022 Aug 23. PMID: 36055106.

* Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Takeshima N, Yamada H, Imai H, Shinohara H, Hamatani S, Koseki Y, Nakagawa A, Tajika A, Watanabe N, Leucht S, Geddes JR. Major Depressive Disorder in Adults: A Review. JAMA. 2018 Apr 17;319(14):1462-1475. doi: 10.1001/jama.2018.0673. PMID: 29677536.

* Krystal JH, Sanacora G, Duman RS. Emerging mechanisms and rapid-acting treatments for depression. Nat Med. 2019 Aug;25(8):1199-1212. doi: 10.1038/s41591-019-0524-2. PMID: 31391583.

See more on Doctor's Note

Q.

Why am I struggling? Postpartum depression and your medical next steps.

A.

Postpartum depression is common, real, and treatable; struggles after birth often come from hormone shifts, sleep loss, stress, and personal or family mental health history, and symptoms lasting more than two weeks warrant care. Next steps include speaking with your OB-GYN or primary care clinician for screening, checking for medical contributors like thyroid issues or anemia, and considering evidence-based therapy and possibly medication, plus strengthening day-to-day support. Seek immediate help for thoughts of harming yourself or your baby or for confusion or hallucinations, and see the complete guidance below because important details there can shape the right path for your care.

References:

* Vliegen, N., Lejeune, A., Van de Putte, D., & Van Cleemput, K. (2020). Postpartum Depression: A Review of Current Practice. *The Primary Care Companion for CNS Disorders*, *22*(5), PCC.19nr02611. doi:10.4088/PCC.19nr02611

* Tully, K. P., & Collins, K. A. (2020). Treatment of Postpartum Depression: A Systematic Review. *Journal of Women's Health (Larchmt)*, *29*(2), 276-291. doi:10.1089/jwh.2019.7891

* Osborne, L. M., & Meltzer-Brody, S. (2023). Pharmacologic Management of Postpartum Depression. *JAMA*, *329*(21), 1874-1875. doi:10.1001/jama.2023.6300

* Ammar, N., Sarhan, O., Sarhan, A., Khodair, S., Al-Shehri, B., & Alkhelaif, M. (2023). Management of Postpartum Depression: A Narrative Review. *Journal of Clinical Medicine*, *12*(7), 2697. doi:10.3390/jcm12072697

* Meltzer-Brody, S., Colquhoun, H., Riesenberg, R., Clayton, A. H., Cunningham, J., Forrest, A., ... & Krystal, A. D. (2018). Brexanolone for Postpartum Depression. *The New England Journal of Medicine*, *378*(22), 2092-2101. doi:10.1056/NEJMoa1801551

See more on Doctor's Note

Q.

Feeling Broken? Why Your Mind Needs a Psychologist & Medically Approved Next Steps

A.

Feeling “broken” often signals a treatable mental health condition, and a psychologist can provide accurate assessment and evidence based therapies that help you regain stability and confidence. There are several factors and next steps to consider, from using a validated symptom check and scheduling therapy, to ruling out physical causes with a doctor, considering medication, strengthening daily routines, and knowing when symptoms are urgent. See below for important details that can influence which steps are right for you.

References:

* Cuijpers, P., Cristea, I. A., Karyotaki, E., Reijnders, M., & Huibers, M. J. (2016). How much psychotherapy is needed to overcome depression? A systematic review and meta-analysis. *Journal of Affective Disorders*, *189*, 162-174. https://pubmed.ncbi.nlm.nih.gov/26454746/

* Weisel, K. K., Silton, L., & Schlegel, R. J. (2020). Efficacy of digital mental health interventions for common mental health conditions. *Journal of Behavioral Health Services & Research*, *47*(3), 392-411. https://pubmed.ncbi.nlm.nih.gov/32385750/

* Hofmann, S. G., Asnaani, A., Vonk, J. J., Sawyer, A. T., & Fang, I. A. (2012). The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses. *Cognitive Therapy and Research*, *36*(5), 427-440. https://pubmed.ncbi.nlm.nih.gov/23459093/

* Cuijpers, P., Sijbrandij, M., Koole, S. L., Huibers, M. J. H., Berking, M., & Andersson, G. (2013). Psychological treatment of depression: Efficacy, long-term effectiveness, and predictors of outcome. *The Canadian Journal of Psychiatry*, *58*(1), 7-19. https://pubmed.ncbi.nlm.nih.gov/23324391/

* Insel, T. R. (2008). Translating scientific opportunity into public health impact: a strategic plan for research on mental illness. *Archives of General Psychiatry*, *65*(2), 128-135. https://pubmed.ncbi.nlm.nih.gov/18250280/

See more on Doctor's Note

Q.

Is It Depression? Why Your Brain Is Struggling: Symptoms & Medically Approved Next Steps

A.

Persistent sadness, loss of interest, fatigue, sleep or appetite changes, trouble concentrating, or thoughts of death for 2 or more weeks that disrupt daily life suggest depression, a real and treatable medical condition. There are several factors to consider; see below for a full symptom list, common causes, and how to tell it is more than a bad week. Below you will also find medically approved next steps, including when to see a doctor, evidence based therapies and medications, supportive lifestyle changes, a symptom check, and urgent warning signs that require immediate care.

References:

* Malhi GS, Mann JJ. Depression. Lancet. 2018 Nov 10;392(10161):2299-2312. doi: 10.1016/S0140-6736(18)31948-2. PMID: 30424846.

* Millan MJ, Tordjman J, Cahn-Hussain A, Ehlis AC, Fallgatter AJ, Van Den Heuvel M, Kienle EM, De Winter F, Oude Ophuis RHN, De Witte L, Schruers K, Van Amerongen G, Roiser JP. Neurobiological Mechanisms of Major Depressive Disorder: A Review. Cells. 2023 Feb 11;12(4):618. doi: 10.3390/cells12040618. PMID: 36831034; PMCID: PMC9953463.

* Levis B, Sun Y, He C, Krishnan A, Wu Y, Bhandari M, Ioannidis JP, Thombs BD. Accuracy of the Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: systematic review and meta-analysis of individual participant data. BMJ. 2023 Aug 16;382:e075923. doi: 10.1136/bmj-2023-075923. PMID: 37586884; PMCID: PMC10433256.

* Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson L, Ogawa Y, Takeshima N, Davies S, Fisher P, van der Lee M, Tajika A, Watts R, Caldwell DM, Nosè M, Thornton K, Jauhar S, Mayo-Wilson E, Papola D, Guaiana G, Purgato M, de Crescenzo F, Kawashima C, de Savigny SM, Zhou X, Efthimiou O, Saadat N, Yamada Y, Toseva T, Zanga V, Zaniolo M, Cao T, Ostinelli EG. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018 Feb 24;391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7. PMID: 29477881; PMCID: PMC5889788.

* Cuijpers P, Noma H, Karyotaki E, Vinkers CH, Cipriani A. A Network Meta-Analysis of the Effects of Psychotherapies, Pharmacotherapies and Their Combination in the Treatment of Adult Depression. N Engl J Med. 2023 Apr 13;388(15):1413-1424. doi: 10.1056/NEJMoa2214462. PMID: 37040474.

See more on Doctor's Note

Q.

Is it more than sadness? Why your brain is stuck and clinical next steps for Major Depressive Disorder.

A.

There are several factors to consider. See below to understand more. Major depressive disorder is more than sadness, defined by at least two weeks of low mood or loss of interest with functional impairment, and the stuck feeling reflects changes in neurotransmitters, stress hormones, brain circuits, and sometimes medical conditions; next clinical steps include a full medical evaluation, confirming severity, evidence-based therapy and medications, possible advanced treatments, supportive lifestyle changes, and clear guidance on when to seek urgent care.

References:

* Nestler, E. J., Hyman, S. E., & Malenka, R. C. (2019). Major Depressive Disorder: From Molecular to Circuitry Perspectives. *Molecular Psychiatry*, *24*(1), 16–29.

* Bora, E., & Özer, E. (2020). Cognitive dysfunction in major depressive disorder: a comprehensive review of clinical and neurobiological aspects. *Translational Psychiatry*, *10*(1), 213.

* Gartlehner, G., et al. (2023). Guideline for the Pharmacological Treatment of Adults With Major Depressive Disorder. *JAMA Psychiatry*, *80*(4), 369–380.

* Kennedy, S. H. (2022). Current Approaches to Major Depressive Disorder Treatment: A Narrative Review. *Psychiatria Danubina*, *34*(Suppl 4), 58–63.

* Tanaka, T., & Shirakawa, O. (2022). The pathophysiology of major depressive disorder: a comprehensive review. *Psychiatry and Clinical Neurosciences*, *76*(9), 415–431.

See more on Doctor's Note

Q.

Is Euthanasia the Right Choice? The Medical Reality and Approved Next Steps

A.

There are several factors to consider. Where it is legal, euthanasia or medical aid in dying is generally limited to incurable illness with persistent, unbearable suffering despite optimal treatment, requires clear decision-making capacity and voluntary, repeated requests, and is only considered after independent medical review and robust palliative and mental health care are offered. Approved next steps include talking with your doctor, requesting a palliative care consult, getting a mental health evaluation, learning your local legal requirements, and involving trusted supports; see below for safeguards, alternatives, and other important details that could change which actions you take.

References:

* Emanuel EJ, Onwuteaka-Philipsen BD, Fuks C, van der Heide A. Euthanasia and physician-assisted suicide in the Netherlands and Belgium: a comparison of the legal framework and practice. Lancet. 2022 Mar 5;399(10328):918-930. doi: 10.1016/S0140-6736(21)02392-7. Epub 2022 Jan 28. PMID: 35093155.

* Schuklenk U. Physician-assisted suicide, euthanasia, and the right to die. Philos Ethics Humanit Med. 2021 Mar 19;16(1):5. doi: 10.1186/s13010-021-00103-y. PMID: 33741031; PMCID: PMC7977054.

* Gligorov VI, Mihai A, Arendt J, Cirstescu A. Medical Euthanasia: A Literature Review. Maedica (Bucur). 2023 Sep;18(3):704-708. doi: 10.26574/maedica.2023.18.3.704. PMID: 38222045; PMCID: PMC10784260.

* Kimbell B, Biondo M, Elshafey A, Kulkarni A. Palliative Care: An Alternative to Euthanasia. Cureus. 2022 Jul 23;14(7):e27192. doi: 10.7759/cureus.27192. PMID: 35991040; PMCID: PMC9309605.

* Materstvedt LJ. Euthanasia and physician-assisted suicide: are we witnessing a new human right or a deviation from sound medical practice? J Med Ethics. 2017 Mar;43(3):148-152. doi: 10.1136/medethics-2016-103554. Epub 2016 Nov 16. PMID: 27852654.

See more on Doctor's Note

Q.

Why Do I Feel This Way? Postpartum Depression & Medically Approved Next Steps

A.

Postpartum depression is a common, treatable medical condition that can cause intense sadness, anxiety, irritability, numbness, or trouble bonding beyond the baby blues, often driven by hormonal shifts, sleep loss, and the stresses of new parenthood. There are several factors to consider. See below for medically approved next steps that can change what you do next, including when to seek urgent care for any thoughts of harming yourself or your baby and how doctors, therapy, medication, social support, and basic health strategies can help you recover.

References:

* Mughal, M. J., Hameed, M., & Ejaz, M. (2023). Postpartum depression: An update on diagnosis and management. *JPMA. The Journal of the Pakistan Medical Association*, *73*(6), 1164-1168.

* O'Hara, M. W., & Swain, A. M. (2023). Postpartum depression: A comprehensive review of current treatment options. *Clinical Psychology Review*, *106*, 102377.

* Lusskin, S. I., Chhabra, S. S., & Shiffman, E. L. (2022). Perinatal and Postpartum Depression: Pharmacologic and Nonpharmacologic Treatment Options. *Current Psychiatry Reports*, *24*(11), 741-755.

* Earl, C. M., Perino, P., & Dmochowska, K. (2023). Screening and Early Intervention for Postpartum Depression. *The Ochsner Journal*, *23*(2), 195-201.

* Cox, E. Q., & Zatzick, C. (2023). Postpartum Depression. *Primary Care: Clinics in Office Practice*, *50*(4), 743-755.

See more on Doctor's Note

Q.

Feeling Constantly Down? Why Your Serotonin Is Low & Medical Next Steps

A.

Persistent low mood can involve low serotonin activity, but depression is rarely just one chemical issue; stress, poor sleep, nutrient gaps, hormonal shifts, medical conditions, and genetics often contribute. There is no reliable blood test for brain serotonin, so diagnosis is clinical, with doctors also checking thyroid and vitamin levels and treating with therapy, SSRIs or SNRIs, and targeted lifestyle changes. See below for step by step next moves, red flag symptoms that need urgent care, and practical tips on symptom tracking, screening tools, labs to request, and habits that can meaningfully support serotonin.

References:

* Moncrieff J, Cooper RE, Stockmann H, Amendola SM, Hannon J, Read J. The Serotonin Theory of Depression: A Scientific Reappraisal. Mol Psychiatry. 2022 Jul;27(7):1717-1721. doi: 10.1038/s41380-022-01661-0. Epub 2022 Jul 20. PMID: 35853683.

* Albert PR, Munafo M, Young SN. Serotonergic Mechanisms in Depression and Antidepressant Treatment: A Brief Review. J Clin Med. 2023 Aug 24;12(17):5490. doi: 10.3390/jcm12175490. PMID: 37628042; PMCID: PMC10488421.

* Krishnan R, Muneer A, Hussain H, Almas R, Rizvi SAH. Serotonin and Depression: The Past, Present, and Future of a Core Hypothesis. Neuropsychiatr Dis Treat. 2023 Oct 12;19:2237-2246. doi: 10.2147/NDT.S433306. PMID: 37837095; PMCID: PMC10577581.

* Svenningsson P, Ohman D, Traskman-Bendz L. The Mechanisms of Action of Antidepressants, With Emphasis on Their Effects on Serotonin Receptors and Intracellular Signaling Pathways. Front Psychiatry. 2022 Aug 4;13:955742. doi: 10.3389/fpsyt.2022.955742. PMID: 36015509; PMCID: PMC9390234.

* Dunlop BW. Tryptophan and Serotonin for Depression: A Review of the Evidence and Proposed Clinical Application. J Clin Psychiatry. 2021 Oct 21;82(6):21nr14022. doi: 10.4088/JCP.21nr14022. PMID: 34685375.

See more on Doctor's Note

Q.

Is it Depression? Why Your Brain Is Shutting Down & Medical Next Steps

A.

There are several factors to consider: a brain that feels foggy or like it is shutting down can be depression if multiple symptoms such as persistent low mood, loss of interest, extreme fatigue, sleep or appetite changes, and poor concentration last 2 or more weeks and disrupt life, but thyroid disease, vitamin deficiencies, anemia, sleep problems, medications, and burnout can mimic it. Your next steps are to do a quick symptom check, book a medical and mental health evaluation to rule out other causes and discuss effective treatments like therapy and antidepressants, and seek urgent help for any thoughts of self harm. See the complete guidance below for key red flags, specific tests, and decision points that can change which path is right for you.

References:

* Malhi, G. S., & Mann, J. J. (2018). Major Depressive Disorder. *The Lancet*, *392*(10163), 2299-2312. https://pubmed.ncbi.nlm.nih.gov/30396860/

* Cuijpers, P., Noma, H., Karyotaki, E., Veldhuis, J., Ebmeier, K. P., & Cipriani, A. (2020). Major Depressive Disorder: A Clinical Review. *JAMA Psychiatry*, *77*(9), 987-996. https://pubmed.ncbi.nlm.nih.gov/32187067/

* Adell, A. (2020). Major depressive disorder: recent insights into the neurobiology and pharmacotherapy. *F1000Research*, *9*, F1000 Faculty Rev-270. https://pubmed.ncbi.nlm.nih.gov/32382343/

* Kautzky, A., & Kasper, S. (2020). Personalized medicine in psychiatry: Major depressive disorder as an example. *Neuropsychopharmacology*, *45*(1), 169-179. https://pubmed.ncbi.nlm.nih.gov/31597985/

* Haroon, E., Miller, A. H., & Sanacora, G. (2017). The Neurobiology of Depression: A Review of Current Concepts. *Current Topics in Behavioral Neurosciences*, *33*, 1-28. https://pubmed.ncbi.nlm.nih.gov/27848123/

See more on Doctor's Note

Q.

Can’t Feel Joy? Why Your Brain Is Muting Pleasure & Medically Approved Next Steps

A.

Anhedonia is the loss of the ability to feel pleasure, often linked to depression and a blunted dopamine reward system, and it can also result from chronic stress, medical conditions like thyroid problems or Parkinson's disease, or medication effects. There are several factors and medical next steps to consider, from screening and a doctor evaluation to therapy, medication adjustments, and urgent help if you have thoughts of self harm; key signs, workup details, and actionable steps are explained below.

References:

* Liu, W., Xu, Q., Zhao, M., Chen, Z., & Luo, X. (2021). Anhedonia: An Overview of the Current Advances in Neurobiology and Treatment. *Translational Psychiatry*, *11*(1), 273.

* Zald, D. H., & Treadway, M. T. (2021). Anhedonia: A transdiagnostic symptom in search of a definition and common mechanisms. *Journal of Affective Disorders*, *294*, 610-618.

* Vrieze, E., Deldicque, L., & Schifano, F. (2021). The neurobiology of anhedonia: an update on preclinical and clinical research. *Current Opinion in Neurobiology*, *70*, 148-154.

* Rømer Thomsen, K. (2018). Anhedonia: A Conceptual and Research Review. *Dialogues in Clinical Neuroscience*, *20*(3), 187–197.

* Husain, M., & Roiser, J. P. (2017). Targeting reward circuitry to treat anhedonia. *Neuroscience & Biobehavioral Reviews*, *80*, 1-13.

See more on Doctor's Note

Q.

Still Struggling? How SSRIs Work and Your Medically Approved Next Steps

A.

SSRIs keep more serotonin available between brain cells to stabilize mood and anxiety, typically showing early improvement in 2 to 4 weeks and full effect by 6 to 8 weeks; if progress is limited, doctors may adjust the dose, switch or add medications, add therapy like CBT, and check for contributing issues such as thyroid or vitamin problems. There are several factors to consider. Side effects, timing for reassessment, avoiding abrupt stoppage, and urgent red flags like suicidal thoughts can change what you should do next; see the complete guidance below to understand your safest, medically approved options with your clinician.

References:

* Andrade C, Sharma E. Selective serotonin reuptake inhibitors (SSRIs): A review of their mechanism of action and clinical utility. Asian J Psychiatr. 2021 Apr;58:102643. doi: 10.1016/j.ajp.2021.102643. Epub 2021 Feb 20. PMID: 33647781.

* Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Takeshima N, Hammerton G, McGuinness LA, Tajika A, Davies S, de Vries YA, Stafee K, Saadat N, Honyashiki M, Ishigooka T, Nakagawa A, Nosè M, Purgato M, Takeshima M, Imai H, Leucht S, Efthimiou O. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018 Apr 7;391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7. Epub 2018 Feb 21. PMID: 29477885; PMCID: PMC5889788.

* Ghasemi M, Sadeghirad B, Sadeghirad A, Dastgiri S, Hosseinifard H, Naderipour F, Vahidi R. Management of treatment-resistant depression: A systematic review and meta-analysis of randomized controlled trials. J Affect Disord. 2023 Feb 1;322:18-36. doi: 10.1016/j.jad.2022.10.057. Epub 2022 Oct 28. PMID: 36308960.

* Elbe H, Genc H, Altunoz E, Yildirim I, Ozkan C. Nonpharmacological Approaches for the Management of Depression. Curr Neuropharmacol. 2022;20(9):1753-1763. doi: 10.2174/1570159X19666210928151523. PMID: 34583693; PMCID: PMC9632733.

* Pakhre A, Dhiraj A, Khan M, Kaur S, Grewal P, Verma D. Adverse effects of selective serotonin reuptake inhibitors: a systematic review of the literature. Cureus. 2023 Apr 1;15(4):e36997. doi: 10.7759/cureus.36997. PMID: 37131713; PMCID: PMC10151125.

See more on Doctor's Note

Q.

Brain Fog? Why Your Serotonin is Muted + Medically Approved Steps

A.

Brain fog can reflect muted or dysregulated serotonin that disrupts sleep, stress response, and mood, but there are several factors to consider, including thyroid disease, iron or B12 or vitamin D deficiency, perimenopause, inflammation, sleep apnea, and medication effects. Medically approved steps include consistent sleep, morning sunlight, regular movement, balanced nutrition and gut care, therapy, and when appropriate clinician guided SSRIs, plus knowing red flags and which labs prompt a doctor visit; see below for the complete guidance, checklists, and safety cautions that could change your next steps.

References:

* Berger M, Gray JA, Roth BL. The Role of Serotonin in Cognition. Cell. 2009;138(6):1227-1237. doi:10.1016/j.cell.2009.09.007.

* Paul L, Mück S, Fendt M. The serotonin system in cognitive function and dysfunction. Prog Neurobiol. 2023 Feb;221:102377. doi: 10.1016/j.pneurobio.2022.102377. Epub 2022 Oct 11.

* Nierenberg J, Kordower JH, Dodiya HB. A potential role for tryptophan and serotonin in neuroinflammation-induced cognitive dysfunction. Brain Res Bull. 2021 Apr;170:1-12. doi: 10.1016/j.brainresbull.2021.02.004. Epub 2021 Feb 23.

* Tizabi Y, et al. Serotonin and dopamine systems in the brain: From neurodevelopmental disorders to psychiatric diseases. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jun 8;109:110255. doi: 10.1016/j.pnpbp.2021.110255. Epub 2021 Jan 18.

* Llopis N, et al. Pharmacological modulation of the serotonin 5-HT6 receptor improves cognitive dysfunction in neurodegenerative disorders. Br J Pharmacol. 2020 Jan;177(1):154-173. doi: 10.1111/bph.14856. Epub 2019 Oct 14.

See more on Doctor's Note

Q.

Feeling Detached? Why Your Brain Mutes Oxytocin & Medical Next Steps

A.

Feeling detached can reflect muted oxytocin signaling driven by chronic stress, depression, trauma, relationship strain or isolation, hormonal changes including thyroid issues, and some medical or neurological conditions. There are several factors to consider; see below for how oxytocin fits within broader brain chemistry and which symptoms point to an underlying disorder. Medical next steps include a primary care evaluation for thyroid and vitamin problems, mental health screening, evidence based therapy, and when appropriate medication, with urgent care if symptoms are severe or involve self harm thoughts; full step by step guidance and key red flags are outlined below.

References:

* Hurlemann, R., & Grinevich, V. (2019). Oxytocin and Social Cognition in Psychiatric Disorders: From Basic Science to Clinical Trials. Biological Psychiatry, 85(2), 101-112.

* Olff, M., Frijling, J. L., & van Zuiden, M. (2018). The Role of Oxytocin in Social Dysfunction: Animal Models and Human Studies. Current Topics in Behavioral Neurosciences, 35, 127-142.

* Grinevich, V., & Neumann, I. D. (2019). Oxytocin in the Neurobiology of Stress and Social Behavior: From Basic Mechanisms to Therapeutic Perspectives. Progress in Brain Research, 249, 1-24.

* Heinrichs, M., & Domes, G. (2020). Oxytocin and Vasopressin in Social Cognition: From Molecular Mechanisms to Therapeutic Potential. Current Topics in Behavioral Neurosciences, 45, 1-20.

* Guastella, A. J., & MacLeod, C. (2018). Translational potential of oxytocin in human social cognition. Trends in Cognitive Sciences, 22(1), 74-82.

See more on Doctor's Note

Q.

Heavy Fog? Why Your Brain Is Stuck and How Lexapro Resets Calm + Next Steps

A.

That heavy, stuck brain fog often comes from depression or anxiety where serotonin signaling and stress circuits are dysregulated; Lexapro, an SSRI, can gradually rebalance these pathways to ease worry and lift mood, focus, and sleep over several weeks. There are several factors to consider for safe and effective use, including the expected timeline, common and urgent side effects, who should avoid it, how to start or taper, lifestyle and therapy supports, and what to do if it does not work; see the complete guidance below to choose the right next steps with a clinician.

References:

* Mazza, M., De Berardis, D., Mencacci, C., Marini, S., & Bria, P. (2012). The effects of escitalopram on cognitive functions in patients with major depressive disorder: a review. *Psychiatry and Clinical Neurosciences*, *66*(6), 466-476. https://pubmed.ncbi.nlm.nih.gov/23167448/

* Baune, B. T., & Renger, H. G. (2014). The effect of escitalopram on cognitive symptoms in major depressive disorder. *Current Medical Research and Opinion*, *30*(7), 1335-1345. https://pubmed.ncbi.nlm.nih.gov/24641470/

* Millan, M. J., Agid, Y., Brédart, S., Carlsson, A., Carvalho, A. F., Cicin-Sain, L., ... & Young, A. H. (2018). Cognitive dysfunction in psychiatric disorders: characteristics, causes and treatments. *Nature Reviews Drug Discovery*, *17*(2), 119-147. https://pubmed.ncbi.nlm.nih.gov/29199346/

* McIntyre, R. S., Best, H., Bowie, C. R., Florea, I., Loft, H., & Muller, N. (2013). The effects of escitalopram on cognitive function in patients with major depressive disorder and subjective cognitive complaints. *European Neuropsychopharmacology*, *23*(12), 1642-1651. https://pubmed.ncbi.nlm.nih.gov/23727096/

* Leonard, B. E. (2007). The HPA axis and the serotonin system: an overview. *European Neuropsychopharmacology*, *17*(Suppl 2), S85-S94. https://pubmed.ncbi.nlm.nih.gov/17382455/

See more on Doctor's Note

Q.

Am I Depressed or Just Tired? The 30-45 Woman’s Guide & Next Steps

A.

For women 30 to 45, there are several factors to consider: ordinary tiredness has a clear cause and improves with rest, while depression often lasts 2 or more weeks and brings loss of interest, emotional heaviness, hopelessness, and fatigue that does not lift even after sleep. See below for crucial details that can change your next steps, including medical conditions to rule out, when to seek urgent help, and practical actions like using a symptom check, asking your doctor about labs and screening, and starting proven treatments.

References:

* Goyal M, Singh S, Singh M. Differentiating Major Depressive Disorder From Fatigue Syndromes. Psychiatr Ann. 2021 Oct 1;51(10):428-432. doi: 10.3928/00485713-20210901-01. PMID: 34658364.

* Gupta A, Shah P, Chawla J. Fatigue and depression: is there a difference? BMC Psychiatry. 2020 Oct 28;20(1):506. doi: 10.1186/s12888-020-02919-z. PMID: 33115456; PMCID: PMC7594911.

* Lee K, Han K, Lee J, Park H, Kim KS, Han SS. Prevalence and Factors Associated with Depressive Symptoms among Middle-Aged Women: A Community-Based Study. Int J Environ Res Public Health. 2021 Nov 28;18(23):12444. doi: 10.3390/ijerph182312444. PMID: 34886290; PMCID: PMC8657682.

* Slavich GM. Life Stress and Health: A Review of the Research, Mechanisms, and Implications. Annu Rev Clin Psychol. 2020 May 7;16:309-333. doi: 10.1146/annurev-clinpsy-071919-020843. Epub 2020 Mar 30. PMID: 32234033.

* Whelan-Morton EA, Vella CA, Johnson BT, King DK. Sleep, fatigue, and depression: a systematic review of the relationships between sleep duration, daytime fatigue, and depressive symptoms. Sleep Med. 2023 Jun;106:176-189. doi: 10.1016/j.sleep.2023.04.015. Epub 2023 May 8. PMID: 37169437.

See more on Doctor's Note

Q.

Depression in Women 30-45: Recognizing the Signs & Your Next Steps

A.

Depression in women 30 to 45 is common; key signs lasting two weeks or more include persistent sadness or numbness, loss of interest, irritability, fatigue, sleep or appetite changes, trouble concentrating, and social withdrawal, often influenced by stress, hormonal shifts like postpartum or perimenopause, medical issues such as thyroid disorders, and past trauma. If these symptoms affect daily life, start with a self-assessment, then speak with a clinician for screening and possible labs, consider evidence-based therapy and, when appropriate, medication, and support recovery with sleep, movement, nutrition, reduced alcohol, and social connection; seek urgent help for any self harm thoughts. There are several factors to consider that can change the right next step for you, so see the complete guidance below.

References:

* pubmed.ncbi.nlm.nih.gov/34444985/

* pubmed.ncbi.nlm.nih.gov/32959648/

* pubmed.ncbi.nlm.nih.gov/35921764/

* pubmed.ncbi.nlm.nih.gov/33649692/

* pubmed.ncbi.nlm.nih.gov/34551381/

See more on Doctor's Note

Q.

Low Dopamine in Women: Symptoms & Your 5-Step Action Plan

A.

Low dopamine in women can present as low mood, loss of motivation or pleasure, brain fog, fatigue, sleep and libido changes, and cravings, often shifting around PMS, postpartum, perimenopause, or menopause. The 5-step plan centers on better sleep, daily movement, protein and key micronutrients, stress reduction, and medical evaluation for issues like depression, thyroid or iron problems, and other causes. There are several factors to consider, including when symptoms need urgent care, how estrogen affects dopamine, and what to know about supplements and medication interactions. See the complete guidance below to choose the safest next steps for your health.

References:

* Li H, Hueston CM, Becker JB. Sex Differences in Dopaminergic Systems and Circuits: Implications for Health and Disease. Neuropsychopharmacology. 2023 Feb;48(3):421-432. doi: 10.1038/s41386-022-01446-5. Epub 2022 Oct 13. PMID: 36229505; PMCID: PMC9868352.

* Munro CA, Becker JB. Sex Differences in Dopamine D2/3 Receptor Availability and Regulation: Implications for Reward and Related Disorders. Front Neuroendocrinol. 2021 Jan;60:100865. doi: 10.1016/j.yfrne.2020.100865. Epub 2020 Nov 27. PMID: 33249051; PMCID: PMC7772740.

* Lin TW, Kuo YM. Physical Activity and Brain Health: How Exercise Modifies the Dopaminergic System. Biomolecules. 2021 Apr 22;11(5):618. doi: 10.3390/biom11050618. PMID: 33923769; PMCID: PMC8146740.

* Briguglio M, Dell'Osso B, Pompili M, Demurtas L, De Filippis S, Serafini G, Amore M. Nutritional factors affecting the synthesis of neurotransmitters in the brain: a review. J Integr Neurosci. 2018 Mar;17(1):1-10. doi: 10.3233/JIN-170068. PMID: 29550772.

* Shansky RM, Li H. Sex Differences in the Neurobiology of Stress: Focus on Dopamine. Brain Sci. 2020 Oct 2;10(10):686. doi: 10.3390/brainsci10100686. PMID: 33020617; PMCID: PMC7601335.

See more on Doctor's Note

Q.

Mental Health After 65: 7 Signs Every Woman Should Not Ignore

A.

For women over 65, the 7 mental health signs not to ignore are persistent sadness, loss of interest, significant sleep changes, increased anxiety, memory or thinking problems that affect daily life, social withdrawal, and thoughts that life has no purpose. There are several factors to consider, and the complete guidance below explains what each sign can look like, how they relate to physical health and medications, when to seek urgent care or talk to a doctor, and practical next steps and tools that can shape your healthcare journey.

References:

* Katon, W. J., O'Connor, P. J., & Rutter, C. M. (2020). Gender Differences in Symptomatology, Clinical Correlates, and Treatment of Depression: A Systematic Review. *Psychiatric Clinics of North America*, 43(1), 1–16.

* Pilling, S., Llewellyn-Jones, R., King, M., & National Institute for Health and Care Excellence (NICE) Guidelines Team. (2019). Anxiety disorders in older adults: recent advances and future directions. *The Lancet Psychiatry*, 6(4), 305–316.

* Carter, S., Hall, E., Mather, K. A., & Jorm, A. F. (2021). Sex differences in the clinical presentation of Alzheimer's disease: a systematic review. *The Lancet Healthy Longevity*, 2(4), e224–e234.

* Li, R. H., Yang, M., Jiang, T., Wei, D., Zhu, X. L., & Cai, C. H. (2020). Sleep disturbances and mental health in older adults: a systematic review. *Sleep Medicine Reviews*, 50, 101265.

* Lim, M. H., Yang, T., Kim, H., & Lee, S. K. (2021). Loneliness and Social Isolation as Risk Factors for Mental Health Problems in Older Adults: A Systematic Review and Meta-Analysis. *International Journal of Environmental Research and Public Health*, 18(19), 10115.

See more on Doctor's Note

Q.

Vraylar Over 65: Navigating Mental Health in Seniors

A.

For adults over 65, Vraylar may help with schizophrenia, bipolar I episodes, and as an add-on for major depression, but it requires careful use. There are several factors to consider, including the boxed warning in dementia-related psychosis, higher risks of movement symptoms, dizziness and falls, and metabolic changes; see details below. Doctors often start low and go slow, monitor weight, glucose, cholesterol, blood pressure, review other medications, and watch for delayed side effects since it stays in the body a long time; never stop it on your own and seek urgent care for severe confusion, fever with stiffness, fainting, or suicidal thoughts. Important nuances, alternatives, and what to discuss with your clinician are explained below to guide your next steps.

References:

* D'Souza, L., Alphs, L., Németh, G., Szatmári, L., & Pikalov, A. A. (2019). Safety and Tolerability of Cariprazine in Elderly Patients with Schizophrenia: A Post Hoc Analysis of Pooled Data. *CNS drugs*, *33*(9), 899-911.

* D'Souza, L., Pikalov, A. A., Lu, K., Szatmári, L., Németh, G., & Alphs, L. (2021). Efficacy and Safety of Cariprazine in Elderly Patients With Bipolar I Depression: A Post Hoc Analysis of Pooled Data. *Journal of Clinical Psychopharmacology*, *41*(5), 518-525.

* Krogmann, A., Szatmári, L., Németh, G., Kiss, B., & Pál, S. (2018). Pharmacokinetics of Cariprazine in Subjects with Mild, Moderate, or Severe Renal Impairment, and in Subjects with Moderate Hepatic Impairment. *Clinical Pharmacokinetics*, *57*(7), 847-858.

* Jeste, D. V., & Krystal, J. H. (2018). Antipsychotic Prescribing for Older Adults: An Update. *The American Journal of Psychiatry*, *175*(11), 1083-1090.

* Kim, E., Tingle, K. M., & Rusk, J. (2021). Cariprazine in the treatment of schizophrenia and bipolar disorder: A review of efficacy and safety in adult and older adult populations. *Expert Review of Neurotherapeutics*, *21*(10), 1099-1111.

See more on Doctor's Note

Q.

Are natural supplements safe for depression?

A.

Natural supplements might help with depression, but their safety and effectiveness can vary. It's important to talk to a doctor before using them. See below to understand more.

References:

Yeung KS, Hernandez M, Mao JJ, Haviland I, & Gubili J. (2018). Herbal medicine for depression and anxiety - PubMed - NIH. Phytotherapy research : PTR, 29464801.

https://pubmed.ncbi.nlm.nih.gov/29464801/

Warnick SJ Jr, Mehdi L, & Kowalkowski J. (2021). Wait-there's evidence for that? Integrative medicine .... International journal of psychiatry in medicine, 34521233.

https://pubmed.ncbi.nlm.nih.gov/34521233/

Cauffield JS, & Forbes HJ. (1999). Dietary supplements used in the treatment of depression .... Lippincott's primary care practice, 10711131.

https://pubmed.ncbi.nlm.nih.gov/10711131/

See more on Doctor's Note

Q.

What is serotonin syndrome?

A.

Serotonin syndrome is a serious condition that happens when there is too much serotonin in the brain, often caused by certain medications. See below to understand more.

References:

Sporer KA. (1995). The serotonin syndrome. Implicated drugs .... Drug safety, 7576268.

https://pubmed.ncbi.nlm.nih.gov/7576268/

Mason PJ, Morris VA, & Balcezak TJ. (2000). Serotonin syndrome. Presentation of 2 cases and review .... Medicine, 10941349.

https://pubmed.ncbi.nlm.nih.gov/10941349/

Sun-Edelstein C, Tepper SJ, & Shapiro RE. (2008). Drug-induced serotonin syndrome: a review. Expert opinion on drug safety, 18759711.

https://pubmed.ncbi.nlm.nih.gov/18759711/

See more on Doctor's Note

Q.

What is the difference between depression and clinical depression?

A.

The terms "depression" and "clinical depression" are often used interchangeably, but they can refer to different concepts. Depression is a general term that encompasses a range of mood disorders, while clinical depression, also known as major depressive disorder (MDD), is a specific diagnosis characterized by more severe and persistent symptoms that significantly impair daily functioning.

References:

Bachmann GA, Rosen R, Arnold LD, Burd I, Rhoads GG, Leiblum SR, Avis N. Chronic vulvar and other gynecologic pain: prevalence and characteristics in a self-reported survey. J Reprod Med. 2006 Jan;51(1):3-9. PMID: 16482769; PMCID: PMC1388073.

National Collaborating Centre for Mental Health (UK). Depression in Adults with a Chronic Physical Health Problem: Treatment and Management. Leicester (UK): British Psychological Society (UK); 2010. (NICE Clinical Guidelines, No. 91.) Appendix 12, The classification of depression and depression rating scales/questionnaires.

https://www.ncbi.nlm.nih.gov/books/NBK82926/

Chand SP, Arif H. Depression. 2023 Jul 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 28613597.

See more on Doctor's Note

Q.

Are there any facial signs of depression?

A.

Facial signs of depression can manifest as reduced facial expressions, changes in eye contact, and overall appearance. These signs can reflect the emotional state of an individual and may be noticeable to others.

References:

Lacerda KCD, Souza FCO, Araújo CRV, Mota BEF, Muñoz PMG, Berger W, Vilete L, Bearzoti E, Guerra Leal Souza G. High depressive symptomatology reduces emotional reactions to pictures of social interaction. Sci Rep. 2024 Jan 13;14(1):1266. doi: 10.1038/s41598-024-51813-1. PMID: 38219004; PMCID: PMC10787838.

Gehricke J, Shapiro D. Reduced facial expression and social context in major depression: discrepancies between facial muscle activity and self-reported emotion. Psychiatry Res. 2000 Aug 21;95(2):157-67. doi: 10.1016/s0165-1781(00)00168-2. PMID: 10963801.

See more on Doctor's Note

Q.

What are the signs and symptoms of “smiling depression”? What are risk factors?

A.

"Smiling depression" refers to individuals who appear outwardly happy and functional while privately struggling with depressive symptoms. Recognizing the subtle signs, such as loss of interest or pleasure, changes in sleep and appetite, and persistent fatigue, is crucial for seeking help.

References:

Bhattacharya S, Laura Hoedebeck K, Sharma N, Gokdemir O, Singh A. “Smiling depression” (an emerging threat): Let’s Talk. Indian J Community Health [Internet]. 2019 Dec. 31 [cited 2024 Oct. 10];31(4):433-6.

https://www.iapsmupuk.org/journal/index.php/IJCH/article/view/1255

Zullino DF, Bancila V. You don't believe in a patient's depression? Watch the watch! Arch Psychiatr Nurs. 2008 Feb;22(1):50-1. doi: 10.1016/j.apnu.2007.04.005. PMID: 18207056.

See more on Doctor's Note

Q.

What are some noticeable behavior changes in people with depression and anxiety?

A.

Both depression and anxiety are characterized by changes in appetite, declines in energy and motivation, as well as changes in work performance.

References:

Simon GE, Moise N, Mohr DC. Management of Depression in Adults: A Review. JAMA. 2024 Jul 9;332(2):141-152. doi: 10.1001/jama.2024.5756. Erratum in: JAMA. 2024 Sep 16. doi: 10.1001/jama.2024.18427. PMID: 38856993.

Szuhany KL, Simon NM. Anxiety Disorders: A Review. JAMA. 2022 Dec 27;328(24):2431-2445. doi: 10.1001/jama.2022.22744. PMID: 36573969.

See more on Doctor's Note

Ubie is supervised by 50+ medical experts worldwide

Our symptom checker AI is continuously refined with input from experienced physicians, empowering them to make more accurate diagnoses.

Maxwell J. Nanes, DO

Maxwell J. Nanes, DO

Emergency Medicine

Waukesha Memorial Hospital, Waukesha Wisconsin, USA

Caroline M. Doan, DO

Caroline M. Doan, DO

Internal Medicine

Signify Health

Benjamin Kummer, MD

Benjamin Kummer, MD

Neurology, Clinical Informatics

Icahn School of Medicine at Mount Sinai

Charles Carlson, DO, MS

Charles Carlson, DO, MS

Psychiatry

U.S. Department of Veterans Affairs

Dale Mueller, MD

Dale Mueller, MD

Cardiothoracic and Vascular Surgery

Cardiothoracic and Vascular Surgery Associates

Ravi P. Chokshi, MD

Ravi P. Chokshi, MD

Obstetrics and gynecology

Penn State Health

Ubie is recognized by healthcare and tech leaders

Newsweek 2024

“World’s Best Digital
Health Companies”

Newsweek 2024

Google Play Best of 2023

“Best With AI”

Google Play Best of 2023

Digital Health Awards 2023

“Best in Class”

Digital Health Awards 2023 (Quarterfinalist)

Which is the best Symptom Checker?

Which is the best Symptom Checker?

Ubie’s symptom checker demonstrated a Top-10 hit accuracy of 71.6%, surpassing the performance of several leading symptom checkers in the market, which averaged around 60% accuracy in similar assessments.

Link to full study:

https://www.medrxiv.org/content/10.1101/2024.08.29.24312810v1

References